

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Bevacizumab may prolong progression-free survival of gliomas: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048975
Article Type:	Original research
Date Submitted by the Author:	13-Jan-2021
Complete List of Authors:	Wang, huan; Shaanxi University of Chinese Medicine Xiao-xuan, Fan; Shaanxi University of Chinese Medicine, Affiliated Hospital Xiao-ping , Zhao; Shaanxi University of Chinese Medicine, Affiliated Hospital Wang, kai; Shaanxi University of Chinese Medicine Si-tian, Ma; Shaanxi University of Chinese Medicine Yong-feng, Yang; Shaanxi University of Chinese Medicine
Keywords:	NEUROSURGERY, ONCOLOGY, Head & neck tumours < ONCOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Bevacizumab may prolong progression-free survival of gliomas: a systematic review and meta-analysis

Corresponding author:

Name: Wang Huan *Mailing Address:* Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, West Weiyang Road, Xianyang City, Shaanxi Province, China *E-mail:* :wh2896526547@163.com *Telephone* No.15709280596

Other authors:

Fan Xiao-xuan Brain Surgery, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Shaanxi, China

Zhao Xiao-ping Brain Surgery, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Shaanxi, China

Wang Kai The first Clinical Medical College of Shaanxi University of Traditional Chinese Medicine, Shaanxi, China

Ma Si-tian The first Clinical Medical College of Shaanxi University of Traditional Chinese Medicine, Shaanxi, China

Yang Yong-feng The first Clinical Medical College of Shaanxi University of Traditional Chinese Medicine, Shaanxi, China

Keywords: glioma, progression-free survival, Bevacizumab

Number of words: 2699

ABSTRACT

Objective: This study evaluated the efficacy and safety of bevacizumab in patients with glioma.

Design: Systematic review and meta-analysis.

Data sources: The data were collected using online search criteria from the databases like PubMed, Embase, The Cochrane Library, OVID, CNKI, and CBM database from inception up to April 2020.

Intervention: Bevacizumab (BEV) and other interventions.

Primary and secondary outcome measures: The main indicators included progression-free survival rate and overall survival rate, and the secondary indicators were adverse reactions.

1
2
3
4 **Results:** A total of 10 clinical center trials were included in this study for meta-analysis,
5 including 2392 patients . The results of the meta-analysis showed that the median
6 progression-free survival rate of the BEV group (PFS) was significantly higher than that
7 of the Non-BEV group ($P < 0.00001$). When compared with the PFS rate of each stage,
8 the PFS rate of the BEV group was 6 months (3.31, 95%CI 2.74 to 4.00, $p < 0.00001$), 12
9 months (2.05, 95%CI 1.70 to 2.49, $p < 0.00001$) and 18 months (1.31, 95%CI 1.02 to 1.69,
10 $p = 0.03$). The PFS of the BEV group was higher than that of Non-BEV group at 24
11 months (0.83, 95%CI 0.50 to 1.37, $p = 0.47$). At 30 months (0.62, 95%CI 0.39 to 0.97,
12 $p = 0.04$), the PFS of the Non-BEV group was lower than that of the Non-BEV
13 group. Moreover, we have compared overall survival rate and the five common adverse
14 reactions, including hypertension ,hemorrhage , and cerebral hemorrhage , Proteinuria
15 and thromboembolism .

16
17 **Conclusion:** BEV can significantly prolong the PFS of patients with glioma within 18
18 months and shorten the PFS of patients after 30 months. This limitation may be related
19 to the high incidence of adverse events caused by long-term use of BEV. More
20 prospective studies are needed to verify it in the future.
21

22 **Strengths and Limitations of this study**

- 23 1. We used the Cochrane criteria to assess the risk of bias.
- 24 2. The heterogeneity was explored by sensitivity, sub-group.
- 25 3. the quality of included studies was largely moderate to high.
- 26 4. The preoperative symptoms and the scope and degree of surgical resection are not
27 taken into account.

28 **INTRODUCTION**

29
30 Brain glioma (High-Grade Glioma, HGG) is the most common primary intracranial
31 tumor, accounting for about 27% of central nervous system tumors and 80% of
32 intracranial malignant tumors¹. The median survival time reported with brain glioma is
33 14-16 months². The Surgical intervention combined with radiotherapy and
34 chemotherapy are often followed for treatment of such cases, but because of its high
35 invasive nature, it often relapses in a short time with poor prognosis. The emergence of
36 temozolomide has considerably delayed the development of glioma to some extent, but
37 the survival rate and quality of life of patients are still very low. Therefore, looking for
38 better drugs to prevent and delay the postoperative recurrence of glioma has become
39 the focus of current research. In recent years, more and more studies have shown that
40 malignant glioma is the tumor with the highest degree of vascularization³. The nature of
41 proliferation is characterized by obvious proliferative vascular lumen and with abnormal
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 proliferation of neovascularization which participates in the construction of tumor
5 microenvironment⁴. It is closely related to the growth, invasion, and metastasis of the
6 tumor, and positively correlated with the extent of malignancy and prognosis of the
7 tumor. Recently, the unique biological characteristics of gliomas indicated that
8 angiogenic factors may play an important role in its treatment and have become the
9 focus of research.
10
11

12
13 Humanized anti-vascular endothelial growth factor monoclonal
14 antibody-bevacizumab⁵, as a representative drug of anti-angiogenic therapy, was
15 approved for recurrent glioblastoma by FDA in 2009⁶ and is listed in China in 2010 by
16 CFDA. According to the radiological response rate, bevacizumab has been approved
17 for recurrent glioblastoma in the United States and many other countries^{7,8}. Although
18 bevacizumab (BEV) has become an important part of HGG therapy, the safety and
19 long-term efficacy of BEV are not clear. Therefore, we conducted a clinical
20 meta-analysis to evaluate the safety and adverse reactions of BEV in patients with
21 HGG, in order to provide a reference for clinical application.
22
23
24
25
26
27

28 **METHODS**

29
30 This study was mainly based on the literature research, and hence there was a
31 requirement for ethical identification.
32
33

34 **Search strategy**

35
36 We collected all the clinical experimental studies of anti-angiogenic therapy in the
37 treatment of gliomas, retrieved through a database search including PubMed,
38 Embase, The Cochrane Library, OVID , CNKI, and CBM , from the establishment of the
39 database to April 2020. The search strategy followed included a combination of subject
40 words and free words, and the retrieval strategy was determined after several
41 pre-searches. The main search words included: "glioma", "angiogenesis inhibitors",
42 "vascular endothelial growth factors", "VEGF", and "clinical study". Additionally, we
43 also manually searched the reference list of all articles on this topic to check and
44 enhance the retrieval of other related publications. All search results are evaluated
45 according to the (PRISMA) statement of "preferred reporting items for systematic
46 review and meta-analysis".
47
48
49
50
51
52
53

54 **Selection criteria**

55
56 Studies were included if they fulfilled the following criteria: (1) Study subjects: the
57 participants were patients of any age, whose histology was confirmed to be HGG. They
58 may have undergone any form of surgery to achieve histological diagnosis (biopsy or
59
60

1
2
3
4 resection); (2) Study type: The clinical control study; (3) Intervention: BEV in
5 bevacizumab group must include bevacizumab, which can be used alone or in
6 combination with multiple drugs. The control group (Non-BEV) refers to treatment that
7 does not include anti-angiogenesis, which can be placebo or supportive therapy, or
8 active intervention (such as chemotherapy). (4) Outcome indicators: included in
9 accordance with the following arbitrary outcome indicators: ① main indicators:
10 progression-free survival (PFS)rate, defined as the time from randomization to death or
11 disease progression of any cause, and overall survival(OS) rate, defined as the time
12 from randomization to death. ② key indicators: adverse events classified according to
13 the World Health Organization (WHO) or the General terminology Standard of the
14 National Cancer Institute (NCI-CTCAE (CTCAE2017)), including the percentage of
15 treatment-related deaths.

16
17
18
19
20
21
22
23
24 Studies were excluded if they fulfilled the following conditions: Non-clinical control
25 studies, incomplete abstract information, conference papers, reviews, and case reports.
26 In addition, the literature of repeated publication and incomplete data that cannot
27 extract valid data should also be excluded.
28
29

30 31 32 **Data extraction**

33
34 Literature screening, data extraction, and cross-checking were carried out by two
35 independent researchers according to the initial inclusion and exclusion criteria, and if
36 there were any differences, it was discussed or judged with the assistance of a third
37 person, and contact and supplement the missing data with the author as far as possible.
38 During the literature screening, the title and the abstract were read initially, and after
39 excluding the obviously irrelevant literature, the full text was read to determine whether
40 to include it or not. Upon matching the inclusion criteria of requirements, the following
41 contents were extracted: (1) the basic information, including title, author, published
42 country, publication date, research type; (2) study subjects, including the number of
43 cases in each group, average age; (3) interventional factors, including the specific
44 details of exposure factors, follow-up time, etc.; (4) the outcome indicators.
45
46
47
48
49
50

51 52 **Quality assessment**

53
54 Using the Cochrane collaboration tool, the risk of bias in individual studies was
55 assessed from seven aspects (sequence generation, allocation hiding, uninformed
56 participants and people, incomplete outcome data, selective reports, and other biases
57 and risks)⁹. Finally, each project was evaluated at three levels: low risk, unclear, and
58 high risk. The two authors conducted independent quality assessments and any
59
60

differences among them were resolved through discussions with a third research expert.

Statistical analysis

Analysis of outcome index

PFS, OS, and adverse reactions were analyzed by Meta with RevMan5.1 software. The data were counted by risk ratio (hazard ratio; HR) and odds ratio (Odds ratio; OR). The interval estimation was expressed by 95%CI, and the test level of the effect quantity was $\alpha = 0.05$.

Heterogeneity analysis

The heterogeneity among the included results was analyzed by using the "I²" (the level is $\alpha = 0.1a$). Simultaneously, combined with I² to quantitatively judge the size of heterogeneity, stata15.1 was used for sensitivity analysis, and the method of examining the influence of a single study was used to eliminate them one by one. The consistency of the results obtained after the above transformation shows that the results of Meta-analysis were stable, otherwise, they were regarded as unstable. Publication bias was detected by the funnel chart method.

RESULT

Literature screening

A total of 1108 related literature were obtained in the initial examination. After screening the literature one by one, a total of 1123 patients were included in 10 clinical studies¹⁰⁻¹⁹. The database and the number of documents retrieved are as follows: PubMed (nasty 259), The Cochrane Library (nasty 153), EMBase (nasty 155), CNKI (nasty 118), CBM (nasty 358), WangFang (nasty 65). The flow chart and the results of literature retrieval are shown in figure 1.

The basic characteristics of the inclusion study

For the inclusion study, the basic information for inclusion is completed using pre-developed forms (Tables 1, 2).

Table 1: basic information for inclusion in the study

Study	State	Res	Cases	Ages(exper	Follow-up	Outcom
		earc	(experime	imental /	time	
		h	ntal/	control)		
		type	control)			

Olivier L. Chinot, M.D. ²⁰¹⁴ [10]	France	RCT	458/463	20–84/18–79	The last patient was hospitalized for 17 months.	1and2year survival rates 、 safety and quality of life、 PFS 、 OS
Qianru Zhao ²⁰¹⁶ [11]	China	RCT	25/24	24–71/27–	The median follow-up time was 7.9 months	disease control rate 、 median survival time、 OS 、 PFS
Ulrich Herrlinge r ²⁰¹⁶ [12]	German y	RCT	116/54	25–78/26–78	Long-term follow-up until death	PFS–6、 PFS、 OS
Mark R.Gilbert ²⁰¹⁶ [13]	German y	RCT	320/317	>18	6 cycles	OS、 PFS
Clara Chen ²⁰¹⁴ [14]	Americ a	Non-RCT	57/79/23	30–77/24–82/19–78	>1year	OS、 PFS
Hualong Li ²⁰²⁰ [15]	China	RCT	31/31	18–70/19–69	4 months	PFS6、 DCR、 Adverse reaction
Zhixian Zhang ²⁰¹⁸ [16]	China	RCT	20/20	24–74	5. 2–18mon ths	PFS6、 OS12

Jiaqi Wang ²⁰¹³ [17]	China	RCT	27/27	53.6 ± 9.7 /54.7 ± 8.8	6months-2y ears	RR , DCR , Adverse reaction
Albert Lai ²⁰¹⁰ [18]	Americ a	RCT	70/110	31.3-75.8/ 20.5-90	>42months	OS , PFS , Adverse reaction
B.Chauffert ²⁰¹⁴ [19]	Britain	RCT	60/60	43-69/43-7 1	6 months	OS , PFS , Adverse reaction

Table 2: basic characteristics of the inclusion study

Study	Male	Female	Open biopsy	Partial resectio	Complete resection	experimental/ control
Olivier L. Chinot, M.D ²⁰¹⁴	282 (61.6) /298 (64.4)	176 (38.4) /165 (35.6)	60 (13.1) /44 (9.5)	210 (45.9) /223 (48.2)	188 (41.0) /196 (42.3)	Bevacizumab+ RT - TMZ/ Placebo+RT - TMZ
Qianru Zhao ²⁰¹⁶	14/12	11/12	/	15/16	10/8	BEV+TMZ/TMZ
Ulrich Herrlinge r ²⁰¹⁶	80 (69.0) /34 (63.0)	36 (31.0) /20 (37.0)	0/2 (3.7)	58 (50.0) /2 7 (50.0)	58 (50.0) /25 (46.3)	BEV+IRI/TMZ
Mark R.Gilbert 2016	/	/	/	/	/	Bevacizumab/ Placebo

Clara	30 (53) /45 (57/79/23	34 (60) /4	20 (35) /33 (3 (5) /2 (2)) /	Bevacizumab
Chen	57) /15 (65)	27 (47) /34 (4 (56) /14	42) /9 (39)	0 (0)	monotherapy
2014		43) /8 (35)	(61)			/Bvacizumab
						combination
						/Nonbevacizumab
Hualong	19/18	12/13	/	/	/	TMZ+BEV/TMZ
Li ²⁰²⁰						
Zhixian	22	18	/	18	22	BEV+TMZ/
Zhang						Gamma knife
2018						+TMZ/
Jiaqi	16/14	11/13	/	/	/	TMZ+BEV/TMZ
Wang ²⁰¹³						
Albert	31/40	39/70	2/23	40/40	28/47	RT+TMZ+BV/UC
Lai ²⁰¹⁰						LA/KPLA
						Control
						RT/TMZ
B.Chauffert ²⁰¹⁴	26/23	34/37	/	/	/	BEV+IRI/TMZ
						Z+RT

Offset risk included in the study

The results of the bias risk assessment included in the study are shown in figure 2.

Meta-analysis results

Progression-free survival

1
2
3
4 Six studies^{10,12-14,18-19} reported median progression-free survival (BEV group,
5 n=1160) and Non-BEV group (n=1027). Results: HR=0.71, 95%CI, 0.65 to 0.79;
6 suggested that the median progression-free survival of gliomas treated with BEV was
7 significantly longer than that of malignant gliomas treated with Non-BEV (P<0.00001),
8 as shown A in figure 3 .
9

10
11 Ten studies¹⁰⁻¹⁹ compared PFS ratios at different follow-up between the Bev group
12 and the Non-BEV group. There was a significant difference in the total heterogeneity
13 test ($I^2=71%$, $P<0.00001$), so the random effect model was used. The results showed
14 that the combined OR values of 6 months, 12 months, 18 months, 24 months and 30
15 months are (3.31, 95%CI 2.74 to 4.00, $p<0.00001$), (2.05, 95%CI 1.70 to 2.49,
16 $p<0.00001$), (1.31, 95%CI 1.02 to 1.69, $p=0.03$), (0.83, 95%CI 0.50 to 1.37, $p=0.47$),
17 (0.62, 95%CI 0.39 to 0.97, $p=0.04$), as shown C in figure 3 .
18
19
20
21

22 Overall survival time

23 Six studies^{10,12-14,18-19} reported the median overall survival time, and there was no
24 significant difference in the heterogeneity test ($I^2=72%$, $p=0.54$), so the random effect
25 model was used for data analysis. Results: HR=0.93, 95%CI, 0.75 to 1.16, suggesting
26 that there was no significant difference in median overall survival time between the
27 BEV group and Non-BEV group ($P=0.54$), as shown B in figure 3 .
28
29

30 Six studies^{10,12-14,18-19} compared OS ratios at different follow-up between the Bev
31 group and the Non-BEV group. There was a significant difference in the total
32 heterogeneity test ($I^2=38%$, $P<0.03$). The Random effect model was used, and the
33 results show that the combined OR values of 6 months, 12 months, 18 months, 24
34 months, and 36 months are (4.94, 95%CI 3.60-6.78, $P<0.00001$), (2.62, 95%CI
35 1.96-3.49, $P<0.00001$), (2.06, 95%CI 0.96-4.40, $P=0.05$), (4.02, 95%CI 2.19-7.36,
36 $P<0.00001$), (1.73, 95%CI 0.93-3.23, $P=0.09$), as shown D in figure 3 .
37
38
39
40
41

42 Adverse reaction

43 As shown in figure 4, there were six studies^{10-11,13-15} that compared adverse
44 reactions between the BEV group and the Non-BEV group. There was a significant
45 difference in the total heterogeneity test ($I^2=58%$, $P<0.00001$), and the random effect
46 model was used. The results showed the combined OR values of hypertension,
47 hemorrhage, cerebral hemorrhage, albuminuria, and thromboembolism as follows:
48 hypertension (4.94, 95%CI 3.60 to 6.78, $P<0.00001$), hemorrhage (2.62, 95%CI 1.96 to
49 3.49, $P<0.00001$), cerebral hemorrhage (2.06, 95%CI 0.96 to 4.40, $P=0.05$), proteinuria
50 (4.02, 95%CI 2.19 to 7.36, $P<0.00001$) and thromboembolism (1.73, 95%CI 0.93 to
51 3.23, $P=0.09$).
52
53
54
55
56
57

58 Sensitivity analysis

1
2
3
4 The sensitivity test was used to evaluate the stability of OS, PFS, and adverse
5 reactions in the included literature, which showed that all values remained in the
6 confidence interval on both sides after one by one elimination. Hence, it can be
7 concluded that all the included literature is stable, as shown in figures 5 .
8
9

10 11 Publication bias

12
13 As shown in figures 6, except for the adverse reactions and the funnel chart of the
14 median OS with HR, the publication bias of the funnel chart was higher, while the rest
15 of the funnel chart was mainly concentrated at the top. Moreover, the symmetry was
16 also proper, so it was concluded that the possibility of publication bias was small.
17
18
19

20 21 DISCUSSION

22 According to the histopathological and clinical features, gliomas are divided into
23 astrocytoma, oligodendroglioma, and ependymoma, which are the most common
24 malignant tumors derived from neuroepithelium²⁰. Although the technical level of
25 surgical intervention, radiotherapy, and chemotherapy²¹ in the treatment of glioma has
26 been greatly improved, there is still a high recurrence rate with increased mortality,
27 which necessitates a more effective therapy. Glioma affects the body through a variety
28 of pathophysiological processes, in which angiogenesis plays an important role in the
29 occurrence and development of glioma, hence blocking angiogenesis has become a
30 new direction of treatment. Bevacizumab is an anti-VEGF antibody against vascular
31 endothelial growth factor²², which acts mainly by competing against the binding of
32 VEGF, to VEGFR on the membrane of target cells. Studies reported by Pope et al.²³
33 and others have shown that the high levels of VEGF affect blood vessel density and
34 tumor grade. Some studies have shown that Ang2/Tie2^{24,25} and STAT3²⁶ are two
35 important signal pathways in anti-angiogenic therapy, which play a vital role in
36 inhibiting peritumoral edema and thus increase of neurological symptoms. In order to
37 better understand the advantages and disadvantages of BEV on glioma, we performed
38 this meta-analysis study which can enlighten and provide a better understanding of the
39 efficacy and safety of BEV through a systematic review.
40
41
42
43
44
45
46
47
48
49

50 The results of our study showed that the PFS of the BEV group was higher than
51 that of the Non-BEV group during the follow-up period of < 18 months, but the PFS of
52 the BEV group was lower than that of the Non-BEV. Moreover, among the BEV group
53 when the follow-up time was 30 months, the OS was higher at 6 months and 12 months,
54 but there was no significant difference between the BEV group and Non-BEV group
55 after 12 months. The study of Li YD²⁷ showed that the progression-free survival time at
56 24 months and 36 months in the bevacizumab group was lower than that in the the
57
58
59
60

1
2
3
4 non-bevacizumab group. However, the study result from Liao KL²⁸ showed that the
5 incidence of PFS was higher in newly diagnosed HGG plus BEV, and the combination
6 therapy involving BEV did not improve the OS. The AVAglio²⁹ trial showed that patients
7 treated with bevacizumab had significant advantages in terms of PFS (6.2months vs
8 10.6 months) and quality of life maintenance, but did not show an advantage in terms
9 of OS (16.8months vs 16.7 months). Compared with the patients without bevacizumab,
10 2.2% of patients treated with bevacizumab confirmed pseudo-progression. Meanwhile,
11 9.3% of patients treated with non-bevacizumab³⁰ reported that the median PFS of
12 bevacizumab combined with temozolomide and radiotherapy was nearly twice as high
13 as that of 3-14 months in a single phase 2 clinical trial, but there was no significant
14 improvement in overall survival. Chinot *et al.*³¹ and Gilbert *et al.*³² conducted phase 3
15 clinical trials in the placebo control group, respectively. The results showed that the
16 PFS of the experimental group increased by 40%, 71%, compared with the control
17 group. Brandes³³ *et al.* and Wick³⁴ also concluded that BEV failed to improve the OS of
18 glioma patients in a randomized study of bevacizumab. BEV can increase the
19 progression-free survival time of patients but cannot significantly improve OS.
20
21
22
23
24
25
26
27

28 Studies have shown that long-term use of BEV does not increase patients' PFS, on
29 the contrary, it may decrease PFS over time, due to the adverse reactions caused by
30 BEV. This study showed five common adverse reactions including hypertension,
31 hemorrhage, cerebral hemorrhage, albuminuria, and thromboembolism upon initiating
32 BEV therapy, but the toxicity of antiangiogenic therapy was generally well tolerated. A
33 phase II trial of Japanese study³⁵ showed that the most common side effects were
34 albuminuria, hypertension, hemorrhage, fever, and epilepsy. Studies³⁶ showed that the
35 incidence of adverse reactions above grade 3 was 27.1% to 46.4%. The most common
36 events reported were thromboembolism, hypertension, epilepsy, fatigue, and intestinal
37 perforation. Zhang Li³⁷ evaluated cases from 20 articles about adverse reactions
38 caused by BEV in 357 patients and found that the main adverse reactions were
39 associated with cardiovascular and hematological diseases. Norden³⁸ evaluated 64
40 glioma patients treated with anticoagulants with BEV and those without anticoagulants.
41 The results showed that the rates of intracranial hemorrhage and other bleeding sites
42 in patients treated with anticoagulants were significantly higher than those in patients
43 treated with BEV alone. However, the rate of severe intracranial hemorrhage was
44 within an acceptable range, hence the anticoagulants were recommended for patients
45 with symptomatic venous thrombosis treated with BEV. Therefore, when bevacizumab
46 was used in the clinic, it was necessary to closely observe for any adverse drug
47 reactions, monitor blood pressure, blood coagulation function, and other indexes, and
48 deal with the symptoms in time. We also need more large-scale phase III clinical
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 studies to prove whether PFS can be improved by improving adverse reactions.
5 Collectively, improving the PFS may enhance great economic and survival benefits to
6 the patients and society, and may further reinforce the successful therapeutic
7 applications of BEV in gliomas.
8
9

10 11 **CONCLUSIONS**

12
13 The evidence suggests that BEV can significantly prolong the PFS of patients with
14 glioma within 18 months and shorten the PFS of patients after 30 months. This
15 limitation may be related to the higher incidence of adverse events caused by the
16 long-term use of BEV.
17
18

19 20 **Limitations**

21
22 In this study, the preoperative symptoms and the scope and degree of surgical
23 resection are not taken into account. Hence, a large study in terms of more samples
24 and higher quality clinical parameters may further validate the conclusive evidence.
25
26

27 28 **Declaration:**

29
30 **Contributors** WH、FXXandZXP contributed to conception and design. WK、MST and
31 YYF contributed to data acquisition or analysis and interpretation of data. WH、FXX、
32 ZXP、WK、MSTandYYFwere involved in drafting the manuscript or revising it critically
33 for important intellectual content. All authors have given final approval of the version to
34 be published.
35
36

37
38 **Funding** The authors have not declared a specific grant for this research from any
39 funding agency in the public, commercial or not-for-profit sectors.
40

41
42 **Competing interests** None declared.

43
44 **Patient consent for publication** Not required.

45
46 **Provenance and peer review** Not commissioned; externally peer reviewed.

47
48 **Data sharing:** No additional data are available.
49

50 51 **Picture description**

52
53 In this paper, the pictures are uploaded in a separate form, and the pictures are
54 merged, leaving 6 important and indispensable pictures.
55

56 57 **REFERENCES**

58
59 [1] Brem S, Tsanaclis AM, Gately S, Gross JL, Herblin WF. Immunolocalization of basic fibroblast growth factor
60 to the microvasculature of human brain tumors. *Cancer* 1992; 70: 2673-80.

- 1
2
3
4 [2] Xia S, Lal B, Tung B, et al. Tumor microenvironment tenascin-C promotes glioblastoma invasion and
5 negatively regulates tumor proliferation. *Neuro Oncol*,2015,18 (94):507 -517.
6
7 [3] Stupp R, Pavlidis N, Jelic S. ESMO Minimum Clinical Recommendations for diagnosis, treatment and
8 follow-up of malignant glioma. *Ann Oncol*. 2005; 16 Suppl 1:i64-5.
9
10 [4] Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in
11 randomised trials. *BMJ* 2011; 343:d5928.
12
13 [5] Sweet JA, Feinberg ML, Sherman JH. The role of avastin in the management of recurrent glioblastoma.
14 *Neurosurg Clin N Am*, 2012;23(2):331-341.
15
16 [6] Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin) as
17 treatment of recurrent glioblastoma multiforme. *Oncologist*, 2009;14(11):1131-1138.
18
19 [7] Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab
20 followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J Clin Oncol* 2009;
21 27:740–5.
22
23 [8] Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in
24 combination with irinotecan in recur-rent glioblastoma. *J Clin Oncol* 2009; 27:4733–40.
25
26 [9] Gs HJP. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011).
27 *Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie und Pharmakologie* 2014;5:S38.
28
29 [10] Olivier L, Chinot, M.D., Wolfgang Wick, M.D., Warren Mason, M.D., et al. Bevacizumab plus
30 Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma. *The New England Journal of Medicine*, 2014;
31 370:709-722.
32
33 [11] Zhao Qianru. Efficacy and safety of bevacizumab combined with temozolomide in the treatment of recurrent
34 malignant gliomas. Zhengzhou University, 2016.
35
36 [12] Ulrich Herrlinger, Niklas Schäfer, Joachim P, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in
37 Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized
38 GLARIUS Trial. *Journal of clinical oncology*, 2015; 63:4691.
39
40 [13] Mark R. Gilbert, James J. Dignam, Terri S. Armstrong, A.N.P., Jeffrey S. Wefel. A Randomized Trial of
41 Bevacizumab for Newly Diagnosed Glioblastoma. *The New England Journal of Medicine*, 2014;370:699-708.
42
43 [14] Clara Chen, Arliene Ravelo, Elaine Yu, et al. Clinical outcomes with bevacizumab-containing and
44 non-bevacizumab-containing regimens in patients with recurrent glioblastoma from US community practices.
45 *CLINICAL STUDY*, 2015;DOI 10.1007/s11060-015-1752-y.
46
47 [15] Li Hualong, Qiang Ming, Huang Xiaoqin, Cai Shuhua, Yang Qiwen. Efficacy of bevacizumab combined with
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 temozolomide in the treatment of malignant recurrent gliomas. *Anhui Medicine*, 2020, 41 (01): 66-68.

4
5
6 [16] Zhang Zhixian, Gu Hou, Lin Jian, Cao Hongming, Lei Xuefen, Jiang Lifeng. Clinical efficacy of gamma
7 knife combined with bevacizumab in the treatment of postoperative malignant gliomas. *Journal of Kunming*
8 *Medical University*, 2018 *Journal* 39 (10): 33-century

9
10
11 [17] Wang Jiaqi, Liang Yong, Ouyang Zheng, Liu Chao, Ouyangsong, Tang Hongyu. Clinical analysis of
12 bevacizumab combined with temozolomide in the treatment of glioblastoma. *Oncology Pharmacy*, 2013 pr. 3 (04):
13 274-277.

14
15
16 [18] Albert Lai, Anh Tran, Phioanh L, et al. Phase II Study of Bevacizumab Plus Temozolomide During and After
17 Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme. *JOURNAL OF CLINICAL*
18 *ONCOLOGY*,2010;30:2709.

19
20
21 [19] Chauffert B, Feuvret L, Bonnetain F, et al. Randomized phase II trial of irinotecan and bevacizumab as
22 neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation
23 for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. *Annals of Oncology Official*
24 *Journal of the European Society for Medical Oncology*, 2014, 25(7):1442.

25
26
27 [20] Zhao Ping, Chen Wanqing. *Incidence and death of Cancer in China 2003 May 2007*. Beijing: military
28 *Medical Science Press*, 2012.

29
30
31 [21] Lu Yuntao, Qi Songtao, Ouyanghui, et al. Surgical and therapeutic strategies for recurrent malignant gliomas
32 in refractory sites. *Chinese Journal of Modern Neurological Diseases*.2012 ;12 (6): 682-690.

33
34
35 [22] Cheng Haixia, Wang Yin. Hair cell astrocytoma with vascular central arrangement: case report and literature
36 review. *Chinese Journal of Modern Neurology*.2 013; 13(4):342-348.

37
38
39 [23] Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent glioblastoma treated
40 with bevacizumab. *Neurology*,2011;76(5): 432-437.

41
42
43 [24] Park JS, Kim IK, Han S, et al. Normalization of tumor vessels by Tie2 activation and Ang2 inhibition
44 enhances drug delivery and produces a favorable tumor microenvironment. *Cancer Cell*, 2016 ; 30(6) :
45 953—967.

46
47
48 [25] Labussiare M, Cheneau C, Prahst C, et al. Angiopoietin-2 may be involved in the resistance to
49 bevacizumab in recurrent glioblastoma. *Cancer Invest*, 2016; 34(1): 39—44.

50
51
52 [26] Groot J, Liang J, Kong LY, et al. Modulating antiangiogenic resistance by inhibiting the signal
53 transducer and activator of transcription 3 pathway in glioblastoma. *Oncotarget*, 2012; 3(9): 1036-1048.

54
55
56 [27] Li Y, Hou M, Lu G, et al. The Prognosis of Anti-Angiogenesis Treatments Combined with Standard
57 Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of Randomized Controlled Trials. *Plos One*, 2016,
58 11(12):e0168264.
59
60

- 1
2
3
4 [28] Liao KL, Huang S, Wu YP. The prognosis for patients with newly diagnosed glioblastoma receiving
5 bevacizumab combination therapy: a meta-analysis. *OncoTargets and therapy*. 2018; 11:3513-3520.
6
7 [29] Chinot O, Cloughesy T, Henriksson R, et al. Efficacy and safety of bevacizumab (Bv) plus standard
8 combination temozolomide (T) and radiotherapy (RT) in newly diagnosed glioblastoma: final results from a AVA
9 glioma. *Eur J Cancer* 2013; 49(suppl 2):S774-5.
10
11 [30] Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to standard radiation therapy
12 and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. *Int J*
13 *Radiat Oncol Biol Phys*, 2012, 82(1):58-66.
14
15 [31] Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed
16 glioblastoma. *N Engl J Med* 2014;370:709 - 22.
17
18 [32] Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed
19 glioblastoma. *N Engl J Med* 2014;370:699 - 708.
20
21 [33] Brandes, A.A., Finocchiaro, G., Zagonel, V., Reni, M., Fabi, A., Caserta, C., et al. Final results from the
22 randomized phase II trial average (ML25739) with bevacizumab or fotemustine in recurrent GBM. *Neuro-Oncol*.
23 2014;16: v8 - v22.
24
25 [34] Wick, W., Brandes, A.A., Gorlia, T., Bendszus, M., Sahm, F., Taal, W., et al., 2015. Phase III trial exploring
26 the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC
27 26101 trial. *Neuro-Oncol*.2015;17:v1.
28
29 [35] Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
30 glioblastoma. *J Clin Oncol*.2009;27:4733 - 40.
31
32 [36] Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with
33 recurrent malignant glioma. *Jpn J Clin Oncol*.2012;42:887 - 95.
34
35 [37] Zhang Li. Statistical analysis of adverse reactions caused by bevacizumab. *Clinical Medical Engineering*.
36 2012; 19 (1): 129-130.
37
38 [38] Norden AD , Bartolomeo J , Tanaka S , et al . Safety of concurrent bevacizumab therapy and
39 anticoagulation in glioma patients. *J Neurooncol*.2011,106(1):121-125.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: document screening process and results

168x237mm (120 x 120 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Albert Lai 2010	?	+	?	+	+	+	+	+	+
B Chauffert 2014	?	?	?	+	+	+	+	+	+
Clara Chen 2014	?	?	?	?	+	+	+	+	+
HuaLong Li 2013	?	?	?	+	+	+	+	+	+
Jiaqi Wang 2013	?	?	?	+	+	+	+	+	+
Mark R.Gilbert 2016	?	?	?	+	+	+	+	+	+
Oliver L. Chintot 2014	?	?	?	+	+	+	+	+	+
Qianru Zhao 2016	?	?	?	+	+	+	+	+	+
Ulrich Herrlinger 2016	?	?	?	+	+	+	+	+	+
Zhixian Zhang 2018	-	+	+	?	+	+	+	+	+

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias

Figure 2: bias risk assessment form




Figure 3 shows: A) HR of median PFS in BEV group and Non-BEV group in the treatment of glioma; B) HR of median OS in BEV group and Non-BEV group in the treatment of glioma; C) OR of PFS at each follow-up time in BEV group and Non-BEV group in the treatment of glioma; D) OR of OS at each follow-up time in the treatment of glioma in the BEV group and Non-BEV group




Figure 4: OR of adverse reactions in the treatment of glioma in the BEV group and Non-BEV group

150x196mm (120 x 120 DPI)




Figure 5 shows: Comparison of the sensitivity analysis offunnel at each follow-up time A) PFS6 combined with OR; B) PFS12 combined with OR; C) PFS18 combined with OR; D) PFS24 combined with OR; E) PFS30 combined with OR; F) OS6 combined with OR; G) OS12 combined with OR; H) OS18 combined with OR; I) OS24 combined with OR; J) OS30 combined with OR




Figure 6 shows:A)The forest map shows:A)OS combined with OR funnel at each follow-up time;B) PFS and OR funnel diagram at each follow-up time



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Systematic review and meta-analysis.	
ABSTRACT			
Structured summary	2	<p>Objective: This study evaluated the efficacy and safety of bevacizumab in patients with glioma.</p> <p>Design: Systematic review and meta-analysis.</p> <p>Data sources: The data were collected using online search criteria from the databases like PubMed, Embase, The Cochrane Library, OVID biomedical database, Chinese periodical full-text database (CNKI), and Chinese biomedical literature service system (CBM) from inception up to April 2020.</p> <p>Intervention: Bevacizumab (BEV) and other interventions.</p> <p>Primary and secondary outcome measures: The main indicators included progression-free survival rate and overall survival rate, and the secondary indicators were adverse reactions.</p> <p>Results: A total of 10 clinical center trials were included in this study for meta-analysis, including 2392 patients . The results of the meta-analysis showed that the median progression-free survival rate of the BEV group (PFS) was significantly higher than that of the Non-BEV group (P<0.00001). When compared with the PFS rate of each stage, the PFS rate of the BEV group was 6 months (3.31, 95%CI 2.74 to 4.00, p<0.00001), 12 months (2.05, 95%CI 1.70 to 2.49, p<0.00001) and 18 months (1.31,95%CI 1.02 to 1.69, p=0.03). The PFS of the BEV group was higher than that of Non-BEV group at 24 months (0.83, 95%CI 0.50 to 1.37, p=0.47). At 30 months (0.62, 95%CI 0.39 to 0.97, p=0.04), the PFS of the Non-BEV group was lower than that of the Non-BEV group. Moreover, we have compared overall survival rate and the five common adverse reactions, including hypertension ,hemorrhage , and cerebral hemorrhage , Proteinuria and thromboembolism .</p> <p>Conclusion: BEV can significantly prolong the PFS of patients with glioma within 18 months and shorten the PFS of patients after 30 months. This limitation may be related to the high incidence of adverse events</p>	



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

caused by long-term use of BEV. More prospective studies are needed to verify it in the future.

INTRODUCTION

Rationale

3

Brain glioma (High-Grade Glioma, HGG) is the most common primary intracranial tumor, accounting for about 27% of central nervous system tumors and 80% of intracranial malignant tumors¹. The median survival time reported with brain glioma is 14-16 months². The Surgical intervention combined with radiotherapy and chemotherapy are often followed for treatment of such cases, but because of its high invasive nature, it often relapses in a short time with poor prognosis. The emergence of temozolomide has considerably delayed the development of glioma to some extent, but the survival rate and quality of life of patients are still very low. Therefore, looking for better drugs to prevent and delay the postoperative recurrence of glioma has become the focus of current research. In recent years, more and more studies have shown that malignant glioma is the tumor with the highest degree of vascularization³. The nature of proliferation is characterized by obvious proliferative vascular lumen and with abnormal proliferation of neovascularization which participates in the construction of tumor microenvironment⁴. It is closely related to the growth, invasion, and metastasis of the tumor, and positively correlated with the extent of malignancy and prognosis of the tumor. Recently, the unique biological characteristics of gliomas indicated that angiogenic factors may play an important role in its treatment and have become the focus of research.

Humanized anti-vascular endothelial growth factor monoclonal antibody-bevacizumab⁵, as a representative drug of anti-angiogenic therapy, was approved for recurrent glioblastoma by FDA in 2009⁶ and is listed in China in 2010 by CFDA. According to the radiological response rate, bevacizumab has been approved for recurrent glioblastoma in the United States and many other countries^{7,8}. Although bevacizumab (BEV) has become an important part of HGG therapy, the safety and long-term efficacy of BEV are not clear. Therefore, we conducted a clinical meta-analysis to evaluate the safety and adverse reactions of BEV in patients with HGG, in order to provide a reference for clinical application.

Objectives

4

This study evaluated the efficacy and safety of bevacizumab in patients with glioma.



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

METHODS		
Protocol and registration	5	Not Protocol and registration
Eligibility criteria	6	(1) Study subjects: the participants were patients of any age, whose histology was confirmed to be HGG. They may have undergone any form of surgery to achieve histological diagnosis (biopsy or resection); (2) Study type: The clinical control study; (3) Intervention: BEV in bevacizumab group must include bevacizumab, which can be used alone or in combination with multiple drugs. The control group (Non-BEV) refers to treatment that does not include anti-angiogenesis, which can be placebo or supportive therapy, or active intervention (such as chemotherapy). (4) Outcome indicators: included in accordance with the following arbitrary outcome indicators:① main indicators: progression-free survival (PFS)rate, defined as the time from randomization to death or disease progression of any cause, and overall survival(OS) rate, defined as the time from randomization to death. ② key indicators: adverse events classified according to the World Health Organization (WHO) or the General terminology Standard of the National Cancer Institute (NCI-CTCAE (CTCAE2017)), including the percentage of treatment-related deaths.
Information sources	7	We collected all the clinical experimental studies of anti-angiogenic therapy in the treatment of gliomas, retrieved through a database search including PubMed database, Embase database, The Cochrane Library, CBM, Biomedical database, China Journal full-text database (CNKI), Wanfang, from the establishment of the database to April 2020.
Search	8	The search strategy followed included a combination of subject words and free words, and the retrieval strategy was determined after several pre-searches. The main search words included: "glioma", "angiogenesis inhibitors", "vascular endothelial growth factors", "VEGF", and "clinical study". Additionally, we also manually searched the reference list of all articles on this topic to check and enhance the retrieval of other related publications. All search results are evaluated according to the (PRISMA) statement of "preferred reporting items for systematic review and meta-analysis".
Study selection	9	Studies were included if they fulfilled the following criteria: The above eligibility criteria. Studies were excluded if they fulfilled the following conditions: Non-clinical control studies, incomplete



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		abstract information, conference papers, reviews, and case reports. In addition, the literature of repeated publication and incomplete data that cannot extract valid data should also be excluded.	
Data collection process	10	Literature screening, data extraction, and cross-checking were carried out by two independent researchers according to the initial inclusion and exclusion criteria, and if there were any differences, it was discussed or judged with the assistance of a third person, and contact and supplement the missing data with the author as far as possible. During the literature screening, the title and the abstract were read initially, and after excluding the obviously irrelevant literature, the full text was read to determine whether to include it or not. Upon matching the inclusion criteria of requirements	
Data items	11	the following contents were extracted: (1) the basic information, including title, author, published country, publication date, research type; (2) study subjects, including the number of cases in each group, average age; (3) interventional factors, including the specific details of exposure factors, follow-up time, etc.; (4) the outcome indicators.	
Risk of bias in individual studies	12	Using the Cochrane collaboration tool, the risk of bias in individual studies was assessed from seven aspects (sequence generation, allocation hiding, uninformed participants and people, incomplete outcome data, selective reports, and other biases and risks) ⁹ . Finally, each project was evaluated at three levels: low risk, unclear, and high risk. The two authors conducted independent quality assessments and any differences among them were resolved through discussions with a third research expert.	
Summary measures	13	PFS, OS, and adverse reactions were analyzed by Meta with RevMan5.1 software. The data were counted by risk ratio (hazard ratio; HR) and odds ratio (Odds ratio; OR). The interval estimation was expressed by 95%CI, and the test level of the effect quantity was $\alpha = 0.05$.	
Synthesis of results	14	The heterogeneity among the included results was analyzed by using the "I ² " (the level is $\alpha = 0.1$ a). Simultaneously, combined with I ² to quantitatively judge the size of heterogeneity.	

Section/topic	#	Checklist item	Reported on page #
---------------	---	----------------	--------------------



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Risk of bias across studies	15	Publication bias was detected by the funnel chart method.	
Additional analyses	16	Stata15.1 was used for sensitivity analysis, and the method of examining the influence of a single study was used to eliminate them one by one. The consistency of the results obtained after the above transformation shows that the results of Meta-analysis were stable, otherwise, they were regarded as unstable.	
RESULTS			
Study selection	17	A total of 1108 related literature were obtained in the initial examination. After screening the literature one by one, a total of 1123 patients were included in 10 clinical studies ¹⁰⁻¹⁹ . The database and the number of documents retrieved are as follows: PubMed (nasty 259), The Cochrane Library (nasty 153), EMBASE (nasty 155), CNKI (nasty 118), CBM (nasty 358), WangFang (nasty 65). The flow chart and the results of literature retrieval are shown in figure 1.	
Study characteristics	18	<p>The basic characteristics of the inclusion study</p> <p>For the inclusion study, the basic information for inclusion is completed using pre-developed forms (Tables 1, 2).</p> <p>Offset risk included in the study</p> <p>The results of the bias risk assessment included in the study are shown in figure 2.</p>	
Risk of bias within studies	19	<p>Publication bias</p> <p>As shown in figures 6 (see appendix), except for the adverse reactions and the funnel chart of the median OS with HR, the publication bias of the funnel chart was higher, while the rest of the funnel chart was mainly concentrated at the top. Moreover, the symmetry was also proper, so it was concluded that the possibility of publication bias was small.</p>	



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Results of individual studies	20	<p>Progression-free survival</p> <p>Six studies^{10,12-14,18-19} reported median progression-free survival (BEV group, n=1160) and Non-BEV group (n=1027). Results: HR=0.71, 95%CI, 0.65 to 0.79; suggested that the median progression-free survival of gliomas treated with BEV was significantly longer than that of malignant gliomas treated with Non-BEV (P<0.00001), as shown A in figure 3 .</p> <p>Overall survival time</p> <p>Six studies^{10,12-14,18-19} reported the median overall survival time, and there was no significant difference in the heterogeneity test ($I^2=72%$, $p=0.54$), so the random effect model was used for data analysis. Results: HR=0.93, 95%CI, 0.75 to 1.16, suggesting that there was no significant difference in median overall survival time between the BEV group and Non-BEV group (P=0.54), as shown B in figure 3 .</p> <p>Adverse reaction</p> <p>The results showed the combined OR values of hypertension, hemorrhage, cerebral hemorrhage, albuminuria, and thromboembolism as follows: hypertension (4.94, 95%CI 3.60 to 6.78, P<0.00001), hemorrhage (2.62, 95%CI 1.96 to 3.49, P<0.00001), cerebral hemorrhage (2.06, 95%CI 0.96 to 4.40, P=0.05), proteinuria (4.02, 95%CI 2.19 to 7.36, P<0.00001) and thromboembolism (1.73, 95%CI 0.93 to 3.23, P=0.09).</p>
Synthesis of results	21	<p>Progression-free survival</p> <p>Ten studies¹⁰⁻¹⁹ compared PFS ratios at different follow-up between the Bev group and the Non-BEV group. There was a significant difference in the total heterogeneity test ($I^2=71%$, $P<0.00001$), so the random effect model was used. The results showed that the combined OR values of 6 months, 12 months, 18 months, 24 months and 30 months are (3.31, 95%CI 2.74 to 4.00, $p<0.00001$), (2.05, 95%CI 1.70 to 2.49, $p<0.00001$), (1.31, 95%CI 1.02 to 1.69, $p=0.03$), (0.83, 95%CI 0.50 to 1.37, $p=0.47$), (0.62, 95%CI 0.39 to 0.97, $p=0.04$), as shown C in figure 3 .</p> <p>Overall survival time</p> <p>For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml</p>



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		<p>Six studies^{10,12-14,18-19} compared OS ratios at different follow-up between the Bev group and the Non-BEV group. There was a significant difference in the total heterogeneity test ($I^2=38\%$, $P<0.03$). The Random effect model was used, and the results show that the combined OR values of 6 months, 12 months, 18 months, 24 months, and 36 months are (4.94, 95%CI 3.60-6.78, $P<0.00001$), (2.62, 95%CI 1.96-3.49, $P<0.00001$), (2.06, 95%CI 0.96-4.40, $P=0.05$), (4.02, 95%CI 2.19-7.36, $P<0.00001$), (1.73, 95%CI 0.93-3.23, $P=0.09$), as shown D in figure 3 .</p> <p>Adverse reaction</p> <p>As shown in figure 4, there were six studies^{10-11,13-15} that compared adverse reactions between the BEV group and the Non-BEV group. There was a significant difference in the total heterogeneity test ($I^2=58\%$, $P<0.00001$), and the random effect model was used.</p>	
Risk of bias across studies	22	<p>As shown in figures 6 (see appendix), except for the adverse reactions and the funnel chart of the median OS with HR, the publication bias of the funnel chart was higher, while the rest of the funnel chart was mainly concentrated at the top. Moreover, the symmetry was also proper, so it was concluded that the possibility of publication bias was small.</p>	
Additional analysis	23	<p>The sensitivity test was used to evaluate the stability of OS, PFS, and adverse reactions in the included literature, which showed that all values remained in the confidence interval on both sides after one by one elimination. Hence, it can be concluded that all the included literature is stable, as shown in figures 5 .</p>	
DISCUSSION			
Summary of evidence	24	<p>Studies have shown that long-term use of BEV does not increase patients' PFS, on the contrary, it may decrease PFS over time, due to the adverse reactions caused by BEV. This study showed five common adverse reactions including hypertension, hemorrhage, cerebral hemorrhage, albuminuria, and thromboembolism upon initiating BEV therapy, but the toxicity of antiangiogenic therapy was generally well tolerated. A phase II trial of Japanese study³⁵ showed that the most common side effects were albuminuria, hypertension, hemorrhage, fever, and epilepsy. Studies³⁶ showed that the incidence of adverse reactions above grade 3 was 27.1% to 46.4%. The most common events reported were thromboembolism,</p>	



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

hypertension, epilepsy, fatigue, and intestinal perforation. Zhang Li³⁷ evaluated cases from 20 articles about adverse reactions caused by BEV in 357 patients and found that the main adverse reactions were associated with cardiovascular and hematological diseases. Norden³⁸ evaluated 64 glioma patients treated with anticoagulants with BEV and those without anticoagulants. The results showed that the rates of intracranial hemorrhage and other bleeding sites in patients treated with anticoagulants were significantly higher than those in patients treated with BEV alone. However, the rate of severe intracranial hemorrhage was within an acceptable range, hence the anticoagulants were recommended for patients with symptomatic venous thrombosis treated with BEV. Therefore, when bevacizumab was used in the clinic, it was necessary to closely observe for any adverse drug reactions, monitor blood pressure, blood coagulation function, and other indexes, and deal with the symptoms in time. We also need more large-scale phase III clinical studies to prove whether PFS can be improved by improving adverse reactions. Collectively, improving the PFS may enhance great economic and survival benefits to the patients and society, and may further reinforce the successful therapeutic applications of BEV in gliomas.

Limitations

25

In this study, the preoperative symptoms and the scope and degree of surgical resection are not taken into account. Hence, a large study in terms of more samples and higher quality clinical parameters may further validate the conclusive evidence.

Conclusions

26

The evidence suggests that BEV can significantly prolong the PFS of patients with glioma within 18 months and shorten the PFS of patients after 30 months. This limitation may be related to the higher incidence of adverse events caused by the long-term use of BEV. In this study, the preoperative symptoms and the scope and degree of surgical resection are not taken into account. Hence, a large study in terms of more samples and higher quality clinical parameters may further validate the conclusive evidence.

FUNDING

Funding

27

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit: www.prisma-statement.org.

Page 2 of 2

For peer review only

BMJ Open

Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048975.R1
Article Type:	Original research
Date Submitted by the Author:	26-May-2021
Complete List of Authors:	Wang, huan; Xi'an Jiaotong University Medical College First Affiliated Hospital, Fan, Xiaoxuan; Shaanxi University of Chinese Medicine, The First Affiliated Hospital Zhao, Xiaoping; Shaanxi University of Chinese Medicine, The First Affiliated Hospital wang, kai; Shaanxi University of Chinese Medicine Ma, Sitian; Shaanxi University of Chinese Medicine Yang, Yongfeng; Shaanxi University of Chinese Medicine
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Patient-centred medicine
Keywords:	NEUROSURGERY, ONCOLOGY, Head & neck tumours < ONCOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Efficacy and safety of bevacizumab in the treatment of adult gliomas:a systematic review and meta-analysis

Wang Huan¹ Fan Xiaoxuan² Zhao Xiaoping² Wang Kai³ Ma Sitian³
Yang Yongfeng³

1.The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, 710000

2. Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang , China, 712000

3. Shaanxi University of Traditional Chinese Medicine, Xianyang , China, 712000

Correspondence to Fan Xiaoxuan; szfyfx@163.com

Keywords : glioma,Bevacizumab,efficacy,safety,progression-free survival

Number of words:3833

ABSTRACT

Objective To assess the efficacy and safety of bevacizumab in patients with glioma.

Design Systematic review and meta-analysis.

Participants Adults aged 18 years and above, whose histology was confirmed to be malignant glioma.

Intervention: Bevacizumab and other interventions.

Primary and secondary outcome measures: The main indicators included progression-free survival rate and overall survival rate, and the secondary indicators were adverse reactions.

Results: A total of 10 clinical center trials were included in this study for meta-analysis, including 2392 patients . The results of the meta-analysis showed that the median progression-free survival(PFS) rate of the BEV group was significantly higher than that of the Non-BEV group ($P<0.00001$). When compared with the PFS rate of each stage,it was found that the PFS in the BEV group was higher than that in the Non-BEV group at 6 months (3.31, 95%CI 2.74 to 4.00, $p<0.00001$), 12 months (2.05, 95%CI 1.70 to 2.49, $p<0.00001$) and 18 months (1.31,95%CI 1.02 to 1.69, $p=0.03$).But at 24 months (0.83, 95%CI 0.50 to 1.37, $p=0.47$), there was no significant difference between the two groups.At 30 months (0.62, 95%CI 0.39 to 0.97, $p=0.04$), the PFS of the BEV group was lower than that of the Non-BEV group.Moreover, The results showed that BEV had no significant effect on improving OS, but the adverse reaction in BEV group was significantly higher than that in non-BEV group.

Conclusion:The evidence suggests that BEV can significantly prolong the PFS of patients with glioma within 18 months and shorten the PFS of patients after 30 months. This limitation may be related to the subgroup of patients, the change of recurrence mode, the optimal dose of drug, the increase of hypoxia, the enhancement of invasiveness and so on.Therefore, it is necessary to carry out more samples and higher quality large-scale research in the future.

Strengths and Limitations of this study

1. We used the Cochrane criteria to assess the risk of bias.
2. The heterogeneity was explored by sensitivity, sub-group.
3. the quality of included studies was largely mod-erate to high.
4. The preoperative symptoms and the scope and degree of surgical resection are not taken into account.

INTRODUCTION

Brain glioma is the most common primary intracranial tumor, accounting for about 27% of central nervous system tumors and 80% of intracranial malignant tumors¹. The median survival time reported with brain glioma is 14-16 months². The Surgical intervention combined with radiotherapy and chemotherapy are often followed for treatment of such cases, but because of its high invasive nature, it often relapses in a short time with poor prognosis. The emergence of temozolomide has considerably delayed the development of glioma to some extent, but the survival rate and quality of life of patients are still very low. Therefore, looking for better drugs to prevent and delay the postoperative recurrence of glioma has become the focus of current research. In recent years, more and more studies have shown that malignant glioma is the tumor with the highest degree of vascularization³. The nature of proliferation is characterized by obvious proliferative vascular lumen and with abnormal proliferation of neovascularization which participates in the construction of tumor microenvironment⁴. It is closely related to the growth, invasion, and metastasis of the tumor, and positively correlated with the extent of malignancy and prognosis of the tumor. Recently, the unique biological characteristics of gliomas indicated that angiogenic factors may play an important role in its treatment and have become the focus of research.

Humanized anti-vascular endothelial growth factor monoclonal antibody-bevacizumab⁵, as a representative drug of anti-angiogenic therapy, was approved for recurrent glioblastoma by FDA in 2009⁶ and is listed in China in 2010 by CFDA. According to the radiological response rate, bevacizumab has been approved for recurrent glioblastoma in the United States and many other countries^{7,8}. Although bevacizumab (BEV) has become an important part of HGG therapy, the safety and long-term efficacy of BEV are not clear. Therefore, we conducted a clinical meta-analysis to evaluate the safety and adverse reactions of BEV in patients with HGG, in order to provide a reference for clinical application.

METHODS

This study was mainly based on the literature research, hence there is no need for ethical identification.

Search strategy

We collected all the clinical experimental studies of anti-angiogenic therapy in the treatment of gliomas, retrieved through a database search including PubMed, Embase, The Cochrane Library, WanFang, Chinese periodical full-text database (CNKI), and Chinese biomedical literature service system (CBM), from the establishment of the database to April 2020. The search strategy followed included a combination of subject words and free words, and the retrieval strategy was determined after several pre-searches. The main search words included: "glioma", "angiogenesis inhibitors", "vascular endothelial growth factors", "VEGF", and "clinical study". Additionally, we also manually searched the reference list of all articles on this topic to check and enhance the retrieval of other related publications. All search results are evaluated according to the (PRISMA) statement of "preferred reporting items for systematic review and meta-analysis".

Selection criteria

Studies were included if they fulfilled the following criteria: (1) Study subjects: the participants were adults aged 18 years and above, whose histology was confirmed to be malignant glioma. They may have undergone any form of surgery to achieve histological diagnosis (biopsy or resection); (2) Study type: The clinical control study; (3) Intervention: BEV in bevacizumab group must include bevacizumab, which can be used alone or in combination with multiple drugs. The control group (Non-BEV) refers to treatment that does not include anti-angiogenesis, which can be placebo or supportive therapy, or active intervention (such as chemotherapy). (4) Outcome indicators: included in accordance with the following arbitrary outcome indicators: ① main indicators: progression-free survival rate, defined as the time from randomization to death or disease progression of any cause, and overall survival rate, defined as the time from randomization to death. ② key indicators: adverse events classified according to the World Health Organization (WHO) or the General terminology Standard of the National Cancer Institute (NCI-CTCAE (CTCAE2017)), including the percentage of treatment-related deaths.

Studies were excluded if they fulfilled the following conditions: Non-clinical control studies, incomplete abstract information, conference papers, reviews, and case reports. In addition, the literature of repeated publication and incomplete data that cannot extract valid data should also be excluded.

Data extraction

Literature screening, data extraction, and cross-checking were carried out by two independent researchers according to the initial inclusion and exclusion criteria, and if there were any differences, it was discussed or judged with the assistance of a third person, and contact and supplement the missing data with the author as far as possible. During the literature screening, the title and the abstract were read initially, and after excluding the obviously irrelevant literature, the full text was read to determine whether to include it or not. Upon matching the inclusion criteria of requirements, the following contents were extracted: (1) the basic information, including title, author, published country, publication date, research type; (2) study subjects, including the number of cases in each group, average age; (3) interventional factors, including the specific details of exposure factors, follow-up time, etc.; and (4) the outcome indicators.

Quality assessment

Using the Cochrane collaboration tool, the risk of bias in individual studies was assessed from seven aspects (sequence generation, allocation hiding, uninformed participants and people, incomplete outcome data, selective reports, and other biases and risks)⁹. Finally, each project was evaluated at three levels: low risk, unclear, and high risk. The two authors conducted independent quality assessments and any differences among them were resolved through discussions with a third research expert.

Statistical analysis

Analysis of outcome index

PFS, OS, and adverse reactions were analyzed by Meta with RevMan5.1 software. The dichotomy data is expressed as the combined risk ratio (RR) or risk ratio (hazard ratio; HR), The measurement data is expressed as the mean difference (WMD). The interval estimation was expressed by 95%CI, and the test level of the effect quantity was $\alpha = 0.05$. The test for heterogeneity used I^2 statistics. If there is no significant heterogeneity among studies ($I^2 \leq 50\%$), we used the fixed effects model for data consolidation. While there is significant heterogeneity ($I^2 > 50\%$) between the results of the study, the random effects model for data analysis would be used.

Sensitivity analysis

Simultaneously, stata15.1 was used for sensitivity analysis, adopt the method of examining the impact of individual studies and eliminate them one by one, if the

value obtained is within the confidence interval on both sides, the result is stable. otherwise, they were regarded as unstable. Studies included in literature > 10 were used to detect publication bias by funnel chart.

RESULT

Literature screening

A total of 1108 related literature were obtained in the initial examination. After screening the literature one by one, a total of 1123 patients were included in 10 clinical studies¹⁰⁻¹⁹. The flow chart and the results of literature retrieval are shown in figure 1.

The basic characteristics of the inclusion study

For the inclusion study, the basic information for inclusion is completed using pre-developed forms (Tables 1, 2).

Table 1: basic information for inclusion in the study

Study	State	Res earc h type	Cases (experime ntal/ control)	Ages(exper imental / control)	Follow-up time	Outcom
Olivier L. Chinot, M.D ²⁰¹⁴ [10]	France	RCT	458/463	20-84/18-7 9	The last patient was hospitalize d for 17 months.	1and2year survival rates 、 safety and quality of life、 PFS 、 OS
Qianru Zhao ²⁰¹⁶ [11]	China	RCT	25/24	24-71/27- 8	The median follow-up time was 7.9 months	disease control rate 、 median survival time、 OS 、 PFS
Ulrich Herrlinge r ²⁰¹⁶ [12]	German y	RCT	116/54	25-78/26-7 8	Long-term follow-up until death	PFS-6、 PFS、 OS

Mark R. Gilbert 2016 ^[13]	Germany	RCT	320/317	>18	6 cycles	OS, PFS
Clara Chen 2014 ^[14]	America	Non-RCT	57/79/23	30-77/24-82/19-78	>1year	OS, PFS
Hualong Li 2020 ^[15]	China	RCT	31/31	18-70/19-69	4 months	PFS6, DCR, Adverse reaction
Zhixian Zhang 2018 ^[16]	China	RCT	20/20	24-74	5.2-18months	PFS6, OS12
Jiaqi Wang 2013 ^[17]	China	RCT	27/27	53.6 ± 9.7 / 54.7 ± 8.8	6months-2years	RR, DCR, Adverse reaction
Albert Lai 2010 ^[18]	America	RCT	70/110	31.3-75.8 / 20.5-90	>42months	OS, PFS, Adverse reaction
B.Chaffert 2014 ^[19]	Britain	RCT	60/60	43-69/43-71	6 months	OS, PFS, Adverse reaction

Table 2: basic characteristics of the inclusion study

Study	Male	Female	Open biopsy	Partial resection	Complete resection	experimental/control
Olivier L. Chinot, M.D ²⁰¹⁴	282 (61.6) / 298 (64.4)	176 (38.4) / 165 (35.6)	60 (13.1) / 44 (9.5)	210 (45.9) / 223 (48.2)	188 (41.0) / 196 (42.3)	Bevacizumab+ RT - TMZ / Placebo+RT - TMZ

Qianru Zhao ²⁰¹⁶	14/12	11/12	/	15/16	10/8	BEV+TMZ/TMZ
Ulrich Herrlinge r ²⁰¹⁶	80 (69.0) /34 (63.0)	36 (31.0) /20 (37.0)	0/2 (3.7)	58 (50.0)/2 7 (50.0)	58 (50.0)/25 (46.3)	BEV+IRI/TMZ
Mark R.Gilbert 2016	/	/	/	/	/	Bevacizumab/ Placebo
Clara Chen 2014	30 (53) /45 (57) /15 (65)	57/79/23 27 (47) /34 (43) /8 (35)	34 (60) /4 (61)	20 (35) /33 (42) /9 (39)	3 (5) /2 (2) / 0 (0)	Bevacizumab monotherapy /Becavizumab combination /Nonbecavizu mab
Hualong Li ²⁰²⁰	19/18	12/13	/	/	/	TMZ+BEV/TMZ
Zhixian Zhang 2018	22	18	/	18	22	BEV+TMZ/ Gamma knife +TMZ/
Jiaqi Wang ²⁰¹³	16/14	11/13	/	/	/	TMZ+BEV/TMZ
Albert Lai ²⁰¹⁰	31/40	39/70	2/23	40/40	28/47	RT+TMZ+Bv/UC LA/KPLA Control RT/TMZ
B.Chauffert ²⁰¹⁴	26/23	34/37	/	/	/	BEV+IRI/TMZ Z+RT

Risk of bias assessment

The results of the bias risk assessment included in the study are shown in figure 2.

Meta-analysis results

Progression-free survival

Six studies^{10,12-14,18-19} reported median progression-free survival (BEV group, n=1160) and Non-BEV group (n=1027). There was no significant difference in the heterogeneity test ($I^2=43% < 50%$), so the fixed effect model was used for data analysis. Results suggested that the median progression-free survival of gliomas treated with BEV was significantly longer than that of malignant gliomas treated with Non-BEV (HR=0.71, 95%CI, 0.65 to 0.79, $P < 0.00001$), As shown in figure 3.

Ten studies¹⁰⁻¹⁹ compared PFS ratios at different follow-up between the BEV group and the Non-BEV group. There was a significant difference in the total heterogeneity test ($I^2=71% > 50%$), so the random effect model was used. Through the results found it was found that the PFS in the BEV group was higher than that in the Non-BEV group at 6 months (3.31, 95%CI 2.74 to 4.00, $p < 0.00001$), 12 months (2.05, 95%CI 1.70 to 2.49, $p < 0.00001$) and 18 months (1.31, 95%CI 1.02 to 1.69, $p = 0.03$). But at 24 months (0.83, 95%CI 0.50 to 1.37, $p = 0.47$), $P > 0.05$, so there was no significant statistical difference between the two groups. At 30 months (0.62, 95%CI 0.39 to 0.97, $p = 0.04$), $0.61 < 1$, the diamond pattern falls on the group that supports Non-BEV group, so the PFS of the BEV group was lower than that of the Non-BEV group, as shown in figure 4.

Overall survival time

Six studies^{10,12-14,18-19} reported the median overall survival time, and there was a significant difference in the total heterogeneity test ($I^2=72% > 50%$), so the random effect model was used. Results suggesting that there was no significant difference in median overall survival time between the BEV group and Non-BEV group (HR=0.93, 95%CI, 0.75 to 1.16, $P = 0.54$), as shown in figure 5.

Six studies^{10,12-14,18-19} compared OS ratios at different follow-up between the BEV group and the Non-BEV group. there was no significant difference in the heterogeneity test ($I^2=38% < 50%$), so the fixed effect model was used for data analysis. Through the results found it was found that the OS in the BEV group was higher than that in the Non-BEV group at 6 months (1.41; 95%CI, 1.07-1.84; $P = 0.01$), 12 months (1.31; 95%CI, 1.09-1.58; $P = 0.005$). But at 18 months (0.95; 95%CI, 0.79-1.14; $P = 0.58$), 24 months (1.10; 95%CI, 0.89-1.35; $P = 0.39$), and 30 months (0.90; 95%CI, 0.69-1.18; $P = 0.44$), $P > 0.05$, so there was no significant statistical difference between the two groups, as shown in figure 6.

Adverse reaction

As shown in figure7, there were six studies^{10-11,13-15} that compared adverse reactions between the BEV group and the Non-BEV group. There was a significant difference in the total heterogeneity test ($I^2=58\%>50\%$), and the random effect model was used. The results showed the combined OR values of hypertension, hemorrhage, cerebral hemorrhage, albuminuria, and thromboembolism as follows: hypertension (4.94, 95%CI 3.60 to 6.78, $P<0.00001$), hemorrhage (2.62, 95%CI 1.96 to 3.49, $P<0.00001$), cerebral hemorrhage (2.06, 95%CI 0.96 to 4.40, $P=0.05$), proteinuria (4.02, 95%CI 2.19 to 7.36, $P<0.00001$) and thromboembolism (1.73, 95%CI 0.93 to 3.23, $P=0.09$).Through the results found it was found that the adverse reactions in the BEV group was higher than that in the Non-BEV group .

Sensitivity analysis

The sensitivity test was used to evaluate the stability of OS, PFS, and adverse reactions in the included literature, which showed that all values remained in the confidence interval on both sides after one by one elimination. Hence, it can be concluded that all the included literature is stable, as shown in figures 8,9.

Publication bias

As shown in figures 10, the funnel chart was mainly concentrated at the top. Moreover, the symmetry was also proper, so it was concluded that the possibility of publication bias was small.

DISCUSSION

According to histopathological and clinical features, gliomas are divided into astrocytoma, oligodendroglioma, oligodendroglioma and ependymoma, which are the most common malignant tumors derived from neuroepithelium. Although the technical level of surgery, radiotherapy and chemotherapy²⁰ in the treatment of glioma has been greatly improved, but the recurrence rate and mortality rate are still high, so there is an urgent need for a new treatment. Glioma affects the body through a variety of pathophysiological processes, in which angiogenesis plays an important role in the occurrence and development of glioma, so blocking angiogenesis has become a new direction of treatment. Bevacizumab is an anti-(VEGF) antibody against vascular endothelial growth factor²¹, which acts mainly by competing against VEGF, and binding to VEGFR on the target cell membrane. Pope²² and other studies have shown that the high surface of VEGF affects blood vessel density and tumor grade. Some studies have shown that Ang2/Tie2^{23,24} and STAT3²⁵ are two important signal pathways in anti-angiogenic therapy, which play a good role in inhibiting peritumoral edema and the increase of neurological symptoms. In order to better understand the advantages and

1
2
3
4 disadvantages of BEV on glioma, this study has a better understanding of the
5 efficacy and safety of BEV through systematic review.
6

7 The results of our study showed that the PFS of BEV group was higher than
8 that of Non-BEV group during the follow-up period of < 18 months, but when the
9 follow-up time was 30 months, the PFS of BEV group was lower than that of
10 Non-BEV; meanwhile, It was found that the OS in the BEV group was higher than
11 that in the Non-BEV group at 6 months, 12 months, but after 12 months, there was
12 no statistically significant difference between the BEV group and the non-BEV
13 group. The study of Li YD²⁶ showed that the progression-free survival time at 24
14 months and 36 months in the bevacizumab group was lower than that in the
15 non-bevacizumab group; The results of Liao KL²⁷ showed that a higher incidence of
16 PFS could be obtained by adding BEV to newly diagnosed GB, and this combined
17 treatment did not improve OS. The AVAglio²⁸ trial showed that patients treated with
18 bevacizumab had significant advantages in PFS (6.2 months vs. 10.6 months) and
19 maintenance of life quality, but showed no advantages in OS (16.8 months vs. 16.7
20 months). 2.2% of patients treated with bevacizumab confirmed false progression,
21 compared with 9.3% of patients treated with non-bevacizumab. Vredenburgh²⁹
22 found in a single-group clinical phase 2 experimental study that the median PFS of
23 bevacizumab combined with temozolomide and radiotherapy reached nearly twice
24 the standard of 3-14 months, however the overall survival was not significant
25 improvement. Chinot³⁰ and Gilbert³¹ conducted phase 3 clinical trials with a placebo
26 control group, the results showed that PFS increased by 40%-71% compared with
27 the control group. Special related research on OS, Brandes³² and Wick³³ also found
28 that BEV failed to improve OS of patients with glioma in a randomized study
29 analyzing bevacizumab. From the above research, BEV can improve the PFS of
30 glioma patients within 18 months, but the PFS of patients may be reduced after 30
31 months. It has no obvious significance to improve OS.
32
33
34
35
36
37
38
39
40
41
42
43
44

45 This study showed that after the application of BEV, there were five common
46 adverse reactions: hypertension, hemorrhage, cerebral hemorrhage, albuminuria
47 and thromboembolism. A phase II trial of Japanese³⁴ showed that the most common
48 side effects were albuminuria, hypertension, hemorrhage, fever and epilepsy.
49 Studies³⁵ showed that the incidence of adverse reactions above grade 3 was 27.1%
50 to 46.4%, the most common events were thromboembolism, hypertension, epilepsy,
51 fatigue and intestinal perforation. Zhang Li³⁶ searched 20 articles about adverse
52 reactions caused by BEV, and found that the main adverse reactions were
53 cardiovascular and hematological diseases. Norden³⁷ evaluated 64 glioma patients
54 who received BEV anticoagulant therapy and 64 glioma patients who did not
55
56
57
58
59
60

1
2
3
4 receive anticoagulant therapy, The results showed that the incidence of intracranial
5 hemorrhage and other bleeding in patients treated with anticoagulants was
6 significantly higher than that in patients with BEV alone, but the incidence of severe
7 intracranial hemorrhage was within an acceptable range. Therefore, when using
8 bevacizumab clinically, it is necessary to closely observe drug adverse reactions,
9 monitor blood pressure, coagulation function and other indicators, and deal with
10 symptoms in time.

11
12
13
14 From the above research results, it can be concluded that long-term use of
15 BEV does not increase the patient's PFS, BEV can improve the PFS of glioma
16 patients within 18 months, but the PFS of patients may be reduced after 30 months.
17 Nagham Kaka found³⁸ that BEV could have a role in the treatment of particular
18 subgroups of patients with newly diagnosed GBM. Several studies^{39,40} have found
19 that the median PFS of patients with methylation is longer than that of MGMT
20 unmethylated tumors treated with RT and TMZ combined with BEV. Sandmann and
21 colleagues⁴¹ found that BEV combined with standard TMZ and RT can improve the
22 survival rate of neurotumors, while poorly differentiated mesenchymal tumors may
23 make tumors resistant to BEV over time. Adilijiang and Colleagues⁴² found that
24 treatment with BEV and TMZ results in the upregulation of certain
25 microenvironment related genes in IDH1 mutant tumors in vitro, specifically those
26 involving immune response and extracellular matrix organization. Therefore, The
27 question of whether the limitation of BEV in the treatment of gliomas is due to fixed
28 subsets deserves constant attention.

29
30
31
32
33
34
35
36
37 Studies have shown^{43,44} that antiangiogenic therapy can lead to a transition
38 of glioma to a more aggressive phenotype. In retrospective analysis^{45,46} a trend
39 toward enhanced infiltrative disease was seen in bevacizumab-treated glioma
40 patients suggesting that enhanced tumor inhibition may be a consequence of
41 VEGF signaling blockade. Shiao-Pei Weathers⁴⁷ shows that determining the best
42 biological dose and the subgroup of patients most likely to obtain long-lasting
43 benefits can improve the durability of bevacizumab. Victor A Levin⁴⁸ found
44 treatment for recurrent GBM with BEV appears to improve survival at a dose lower
45 than that in the FDA drug insert. Study⁴⁹ suggest that the higher dosage of BEV
46 utilized may have impacted survival benefits. Animal models⁵⁰ also suggest that
47 higher dose of anti-VEGF treatment, resulting in more hypoxia, may increase tumor
48 aggressiveness. Ryota Tamura⁵¹ found that high doses and long-term use of
49 anti-VEGF/VEGFR may lead to hypoxia. Shiao-Pei Weathers⁴⁷ proposed in tumors
50 where excessive vascular pruning takes place, hypoxia exacerbated by
51 antiangiogenic therapy is likely responsible for initiating a cascade of events. As
52
53
54
55
56
57
58
59
60

1
2
3
4 mentioned above, there are many possible reasons for the limited efficacy of
5 antiangiogenic therapy. But The lack of a long-lasting response to current
6 antiangiogenic treatment underscores the need for a better understanding of how to
7 use antiangiogenic therapy to optimize radiation and chemotherapy treatments.
8
9

10 **CONCLUSIONS**

11 The evidence suggests that BEV can significantly prolong the PFS of patients
12 with glioma within 18 months and shorten the PFS of patients after 30 months. This
13 limitation may be related to the subgroup of patients, the change of recurrence
14 mode, the optimal dose of drug, the increase of hypoxia, the enhancement of
15 invasiveness and so on. BEV treatment has no obvious meaning in improving OS,
16 and it has some side effects, which are acceptable, but we still need to pay close
17 attention to it and take active measures to reduce the side effects. Therefore, it is
18 necessary to carry out more samples and higher quality large-scale research in the
19 future.
20
21
22
23
24

25 **Declaration:**

26 **Contributors** WH、 FXX and ZXP contributed to conception and design. WK、 MST
27 and YYF contributed to data acquisition or analysis and interpretation of data. WH、
28 FXX、 ZXP、 WK、 MST and YYF were involved in drafting the manuscript or revising
29 it critically for important intellectual content. All authors have given final approval of
30 the version to be published.
31
32
33

34 **Funding** This work was supported by Affiliated Hospital of Shaanxi University of
35 Traditional Chinese Medicine, reward/grant number is 2020-ZXY-007.

36 **Ethics Approval** This study belongs to data research and is not applicable to
37 ethical review.
38
39

40 **Competing interests** None declared.
41

42 **Patient and Public Involvement** No patient involved.
43

44 **Provenance and peer review** Not commissioned; externally peer reviewed.
45

46 **Data sharing** All data relevant to the study are included in the article or uploaded
47 as supplementary information.
48
49

50 All the illustrations are as follows:

51 Figure 1: document screening process and results

52 PubMed (n=259), The Cochrane Library (n=153), EMBASE (n=155), CNKI (n=118),
53 CBM (n=358), WanFang (n=65).
54

55 Figure 2: bias risk assessment form
56

57 Figure 3: HR of median PFS in BEV group and Non-BEV group in the treatment of
58 glioma
59
60

1
2
3
4 Fig 4:OR of PFS at each follow-up time in BEV group and Non-BEV group in the
5 treatment of glioma

6
7 Figure 5:HR of median OS in BEV group and Non-BEV group in the treatment of
8 glioma

9
10 Figure 6: OR of OS at each follow-up time in the treatment of glioma in the BEV
11 group and Non-BEV group

12
13 Figure 7: OR of adverse reactions in the treatment of glioma in the BEV group and
14 Non-BEV group

15
16 Figure 8:A: the sensitivity analysis of PFS6 ;B: the sensitivity analysis of PFS12;
17 C:the sensitivity analysis of PFS18;D:the sensitivity analysis of PFS24;E:the
18 sensitivity analysis of PFS30

19
20 Figure 9:A: the sensitivity analysis of OS6 ;B: the sensitivity analysis of OS12;
21 C:the sensitivity analysis of OS18;D:the sensitivity analysis of OS24;E:the
22 sensitivity analysis of OS30

23
24 Figure 10:A: funnel chart of PFS at each follow-up time;B: funnel chart of OS at
25 each follow-up time

26 27 28 29 30 **REFERENCES**

31 1 Brem S,Tsanaclis AM,Gately S,et al.Immunolocalization of basic fibroblast growth
32 factor to the microvasculature of human brain tumors. *Cancer* 1992; 70: 2673-80.

33 2 Xia S,Lal B,Tung B,et al.Tumor microenvironment tenascin-C promotes
34 glioblastoma invasion and negatively regulates tumor proliferation.*Neuro Oncol*
35 2015;18:507 -517.

36 3 Stupp R,Pavlidis N,Jelic S,et al.ESMO Minimum Clinical Recommendations for
37 diagnosis, treatment and follow-up of malignant glioma. *Ann Oncol* 2005; 16 Suppl
38 1:i64-5.

39 4 Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration' s tool
40 for assessing risk of bias in randomised trials. *BMJ* 2011; 343:d5928.

41 5 Sweet JA, Feinberg ML, Sherman JH. The role of avastin in the management
42 of recurrent glioblastoma. *Neurosurg Clin N Am* 2012;23:331-341.

43 6 Cohen MH , Shen YL , Keegan P , et al . FDA drug approval summary:
44 bevacizumab (Avastin) as treatment of recurrent glioblastoma
45 multiforme.*Oncologist* 2009;14:1131-1138.

46 7 Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab
47 followed by bevacizumab plus irinotecan at tumor progression in recurrent
48 glioblastoma. *J Clin Oncol* 2009; 27:740 - 5.

- 1
2
3
4 8 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al.
5 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J*
6 *Clin Oncol* 2009; 27:4733 – 40.
7
8 9 Gs HJP. Cochrane handbook for systematic reviews of interventions version 5.1.0
9 (updated March 2011). *Naunyn-Schmiedebergs Archiv für Experimentelle*
10 *Pathologie und Pharmakologie* 2014;5:S38.
11
12 10 Olivier L. Chinot, M.D., Wolfgang Wick, M.D., Warren Mason, et al.
13 Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma.
14 *The New England Journal of Medicine* 2014; 370:709-722.
15
16 11 Zhao Qianru. Efficacy and safety of bevacizumab combined with temozolomide
17 in the treatment of recurrent malignant gliomas. Zhengzhou University, 2016.
18
19 12 Ulrich Herrlinger, Niklas Schäfer, Joachim P, et al. Bevacizumab Plus Irinotecan
20 Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA
21 Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
22 *Journal of clinical oncology* 2015; 63:4691.
23
24 13 Mark R. Gilbert, James J. Dignam, Terri S. Armstrong, et al. A Randomized Trial
25 of Bevacizumab for Newly Diagnosed Glioblastoma. *The New England Journal of*
26 *Medicine* 2014;370:699-708.
27
28 14 Clara Chen,rliene Ravelo,Elaine Yu,et al.Clinical outcomes with
29 bevacizumab-containing and non-bevacizumab - containing regimens in patients
30 with recurrent glioblastoma from US community practices.CLINICAL STUDY
31 2015;DOI 10.1007/s11060-015-1752-y.
32
33 15 Li Hualong, Qiang Ming, Huang Xiaoqin, et al. Efficacy of bevacizumab
34 combined with temozolomide in the treatment of malignant recurrent gliomas. *Anhui*
35 *Medicine*,2020;41:66-68.
36
37 16 Zhang Zhixian, Gu Hou, Lin Jian, et al.Clinical efficacy of gamma knife
38 combined with bevacizumab in the treatment of postoperative malignant gliomas.
39 *Journal of Kunming Medical University* 2018;39:33-37.
40
41 17 Wang Jiaqi, Liang Yong, Ouyang Zheng, et al. Clinical analysis of bevacizumab
42 combined with temozolomide in the treatment of glioblastoma. *Oncology Pharmacy*
43 2013;3:274-277.
44
45 18 Albert Lai,Anh Tran,Phioanh L,et al.Phase II Study of Bevacizumab Plus
46 Temozolomide During and After Radiation Therapy for Patients With Newly
47 Diagnosed Glioblastoma Multiforme.*JOURNAL OF CLINICAL ONCOLOGY*
48 2010;30:2709.
49
50 19 Chauffert B,Feuvret L,Bonnetain F, et al. Randomized phase II trial of irinotecan
51 and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based
52
53
54
55
56
57
58
59
60

1
2
3
4 chemoradiation compared with temozolomide-chemoradiation for unresectable
5 glioblastoma: final results of the TEMAVIR study from ANOCEF. *Annals of*
6 *Oncology Official Journal of the European Society for Medical Oncology*
7 2014;25:1442.

8
9
10 20 Lu Yuntao, Qi Songtao, Ouyanghui, et al. Surgical and therapeutic strategies for
11 recurrent malignant gliomas in refractory sites. *Chinese Journal of Modern*
12 *Neurological Diseases* 2012;12 (6): 682-690.

13
14 21 Cheng Haixia, Wang Yin. Hair cell astrocytoma with vascular central
15 arrangement: case report and literature review. *Chinese Journal of Modern*
16 *Neurology*. 2013;13:342-348.

17
18
19 22 Pope WB, Xia Q, Paton VE, et al. Patterns of progression in patients with recurrent
20 glioblastoma treated with bevacizumab. *Neurology* 2011;76:432-437.

21
22 23 Park JS, Kim IK, Han S, et al. Normalization of tumor vessels by Tie2 activation
23 and Ang2 inhibition enhances drug delivery and produces a favorable tumor
24 microenvironment. *Cancer Cell* 2016;30:953—967.

25
26 24 Labussiare M, Cheneau C, Prahst C, et al. Angiopoietin-2 may be involved in the
27 resistance to bevacizumab in recurrent glioblastoma. *Cancer Invest* 2016 ;
28 34:39—44.

29
30 25 Groot J, Liang J, Kong LY, et al. Modulating antiangiogenic resistance by
31 inhibiting the signal transducer and activator of transcription 3 pathway in
32 glioblastoma. *Oncotarget* 2012;3(9):1036-1048.

33
34 26 Li Y, Hou M, Lu G, et al. The Prognosis of Anti-Angiogenesis Treatments
35 Combined with Standard Therapy for Newly Diagnosed Glioblastoma: A
36 Meta-Analysis of Randomized Controlled Trials. *Plos One* 2016,11:e0168264.

37
38 27 Liao KL, Huang S, Wu YP. The prognosis for patients with newly diagnosed
39 glioblastoma receiving bevacizumab combination therapy: a meta-analysis.
40 *OncoTargets and therapy* 2018;11:3513-3520.

41
42 28 Chinot O, Cloughesy T, Henriksson R, et al. Efficacy and safety of bevacizumab
43 (Bv) plus standard combination temozolomide (T) and radiotherapy (RT) in newly
44 diagnosed glioblastoma: final results from a AVA glio. *Eur J Cancer* 2013; 49(suppl
45 2):S774-5.

46
47 29 Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to
48 standard radiation therapy and daily temozolomide is associated with minimal
49 toxicity in newly diagnosed glioblastoma multiforme. *Int J Radiat Oncol Biol Phys*
50 2012;82:58-66.

51
52 30 Chinot OL, Wick W, Mason W, et al. Bevacizumab plus
53 radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med*
54 2014;370:709 - 22.

- 1
2
3
4 31 Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab
5 for newly diagnosed glioblastoma. *N Engl J Med* 2014;370:699 – 708.
6
7 32 Brandes, A.A.,Finocchiaro, G.,Zagonel, V.,et al.Final results from the
8 randomized phase II trial average (ML25739) with bevacizumab or fotemustine in
9 recurrent GBM. *Neuro-Oncol* 2014;16:v8 – v22.
10
11 33 Wick, W.,Brandes, A.A.,Gorlia, T.,et al.Phase III trial exploring the combination
12 of bevacizumab and lomustine in patients with first recurrence of a glioblastoma:
13 the EORTC 26101 trial.*Neuro-Oncol* 2015;17:v1.
14
15 34 Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in
16 combination with irinotecan in recurrent glioblastoma. *J Clin Oncol.*2009;27:4733 –
17 40.
18
19 35 Nagane M,Nishikawa R,Narita Y,et al.Phase II study of single-agent
20 bevacizumab in Japanese patients with recurrent malignant glioma.*Jpn J Clin*
21 *Oncol* 2012;42:887 – 95.
22
23 36 Zhang Li. Statistical analysis of adverse reactions caused by bevacizumab.
24 *Clinical Medical Engineering* 2012;19:129-130.
25
26 37 Norden AD,Bartolomeo J,Tanaka S,et al.Safety of concurrent bevacizumab
27 therapy and anticoagulation in glioma patients. *J Neurooncol* 2011;106:121-125.
28
29 38 Nagham Kaka,Karim Hafazalla,Haidar Samawi,et al.Progression-Free but No
30 Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the
31 Treatment of Newly Diagnosed Glioblastoma:A Systematic Review and
32 Meta-Analysis.*Cancers* 2019;11:1723.
33
34 39 Chinot, O.L.;Wick, W.;Mason, W.;et al.Bevacizumab plus
35 radiotherapy-temozolomide for newly diagnosed glioblastoma.*New Engl. J. Med*
36 2014;370:709 – 722.
37
38 40 Gilbert, M.R.;Dignam, J.J.;Armstrong, T.S.;et al.A randomized trial of
39 bevacizumab for newly diagnosed glioblastoma. *New Engl.J.Med* 2014;370:699 –
40 708.
41
42 41 Phillips, H.S.;Kharbanda, S.;Chen, R.;et al. Molecular subclasses of high-grade
43 glioma predict prognosis, delineate a pattern of disease progression, and resemble
44 stages in neurogenesis.*Cancer Cell* 2006;9:157 – 173.
45
46 42 Adilijiang, A.;Hirano, M.;Okuno, Y.;et al.Next generation sequencing-based
47 transcriptome predicts bevacizumab efficacy in combination with temozolomide in
48 glioblastoma. *Molecules* 2019;24:3046.
49
50 43 Piao Y , Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in
51 glioblastoma is associated with a mesenchymal transi-tion.*Clin Cancer Res*
52 2013;19:4392 – 403.
53
54
55
56
57
58
59
60

1
2
3
4 44 Lu KV , Chang JP , Parachoniak CA, et al. VEGF inhibits tumor cell invasion and
5 mesenchymal transition through a MET/VEGFR2 complex.Cancer Cell
6 2012;22:21 - 35.
7

8 45 Norden A,Young G,Setayesh K,et al.Bevacizumab for recurrent malignant
9 gliomas: efficacy, toxicity, and patterns of recurrence.Neurology 2008;70:779 - 87.
10

11 46 Soda Y,Myskiw C,Rommel A, Verma I. Mechanisms of neovas-
12 cularization and
13 resistance to anti-angiogenic therapies in glioblas-toma multiforme. J Mol Med
14 (Berl) 2013;91:439 - 48.
15


16 47 Shiao-Pei Weathers,John de Groot.Resistance to Antiangiogenic Therapy.Curr
17 Neurol Neurosci Rep 2014;14:443.
18

19 48 Victor A.Levin,Nancy D,et al.Mendelssohn,James Chan.Impact of bevacizumab
20 administered dose on overall survival of patients with progressive glioblastoma.J
21 Neurooncol 2015;122:145-50.
22

23 49 Lorgis V,Maura G,Coppa G,et al.Relation between bevacizumab dose intensity
24 and high-grade glioma survival: a retrospective study in two large cohorts.J
25 NeuroOncol 2012,107:351-358.
26

27 50 Keunen O,Johansson M,Oudin A,et al.Anti-VEGF treatment reduces blood
28 supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA
29 Proc Natl Acad Sci U S A 2011;108:3749-54.
30

31 51 Ryota Tamura,Toshihide Tanaka,Yasuharu Akasaki,et al.The role of vascular
32 endothelial growth factor in the hypoxic and immunosuppressive tumor
33 microenvironment: perspectives for therapeutic implications..Med Oncol 2019;37:2.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




45 Figure 1: document screening process and results
 46 PubMed (n=259), The Cochrane Library (n=153), Embase (n=155), CNKI (n=118), CBM (n=358), WanFang
 47 (n=65).

48 168x237mm (120 x 120 DPI)


Albert Lai 2010	?	+	+	+	+	+	+
B. Chauffert 2014	?	?	+	+	+	+	+
Clara Chen 2014	?	?	+	?	+	+	+
HuaLong Li 2013	?	?	+	+	+	+	+
Jiaqi Wang 2013	?	?	+	+	+	+	+
Mark R. Gilbert 2016	?	?	+	+	+	+	+
Oliver L. Chintot 2014	?	?	+	+	+	+	+
Qianru Zhao 2016	?	?	+	+	+	+	+
Ulrich Herrlinger 2016	?	?	+	+	+	+	+
ZhiXian Zhang 2018	+	?	?	?	+	+	+
	Random sequence generation (selection bias)						
	Allocation concealment (selection bias)						
	Blinding of participants and personnel (performance bias)						
	Blinding of outcome assessment (detection bias)						
	Incomplete outcome data (attrition bias)						
	Selective reporting (reporting bias)						
	Other bias						

Figure 2: bias risk assessment form



Figur 3:HR of median PFS in BEV group and Non-BEV group in the treatment of glioma

140x44mm (120 x 120 DPI)



Figur 4:OR of PFS at each follow-up time in BEV group and Non-BEV group in the treatment of glioma

150x223mm (120 x 120 DPI)




Figure 5:HR of median OS in BEV group and Non-BEV group in the treatment of glioma

144x44mm (120 x 120 DPI)




Figure 6: OR of OS at each follow-up time in the treatment of glioma in the BEV group and Non-BEV group

148x206mm (120 x 120 DPI)




Figure 7: OR of adverse reactions in the treatment of glioma in the BEV group and Non-BEV group

150x196mm (120 x 120 DPI)




Figure 8:A: the sensitivity analysis of PFS6 ;B: the sensitivity analysis of PFS12; C:the sensitivity analysis of PFS18;D:the sensitivity analysis of PFS24;E:the sensitivity analysis of PFS30

209x296mm (288 x 288 DPI)




Figure 9:A: the sensitivity analysis of OS6 ;B: the sensitivity analysis of OS12; C:the sensitivity analysis of OS18;D:the sensitivity analysis of OS24;E:the sensitivity analysis of OS30

209x296mm (288 x 288 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 10:A: funnel chart of PFS at each follow-up time;B: funnel chart of OS at each follow-up time

209x296mm (288 x 288 DPI)



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	2
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	3
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	3
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	13-14
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	3
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	4
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	4
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	9
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	4
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	4
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	4
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	4
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	4
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	4-5
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	4-5
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	4
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	4-5



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	5
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	5
Study characteristics	17	Cite each included study and present its characteristics.	5
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	5
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	5-6
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	6
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	6
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	6
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	6
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	6
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	6
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	7-8
	23b	Discuss any limitations of the evidence included in the review.	7-8
	23c	Discuss any limitations of the review processes used.	7-8
	23d	Discuss implications of the results for practice, policy, and future research.	8
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	9
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	9
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	9
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	9
Competing interests	26	Declare any competing interests of review authors.	9
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	9

43

44 From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71

45

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

46

For more information, visit: <http://www.prisma-statement.org/>

47

BMJ Open

Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-048975.R2
Article Type:	Original research
Date Submitted by the Author:	19-Aug-2021
Complete List of Authors:	Wang, huan; Xi'an Jiaotong University Medical College First Affiliated Hospital, Guo, Jianxin; Xi'an Jiaotong University Medical College First Affiliated Hospital Wang, Tianze; Xi'an Jiaotong University wang, kai; Shaanxi University of Chinese Medicine Wu, Zhuojun; Xi'an Jiaotong University Medical College First Affiliated Hospital Sun, Tianze; Xi'an Jiaotong University Medical College First Affiliated Hospital
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Patient-centred medicine
Keywords:	NEUROSURGERY, ONCOLOGY, Head & neck tumours < ONCOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis

Wang Huan¹ Guo Jianxin¹ Wang Tianze² Wang Kai³ Wu Zhuojun¹
Sun Tianze¹

1. The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, 710000
2. Xi'an Jiaotong University, Xi'an, China, 710000
3. Shaanxi University of Chinese Medicine, Xianyang, China, 712000

Correspondence to Guo Jianxin: gjx1665@126.com

Keywords : glioma, Bevacizumab, efficacy, safety, progression-free survival

Number of words: 3923

ABSTRACT

Objective To assess the efficacy and safety of bevacizumab in patients with glioma.

Design Systematic review and meta-analysis.

Participants Adults aged 18 years and above, whose histology was confirmed to be malignant glioma.

Primary and secondary outcome measures: The main indicators included progression-free survival rate and overall survival rate, and the secondary indicators were adverse reactions.

Results: A total of 11 clinical center trials were included in this study for meta-analysis, including 2392 patients. The results of the meta-analysis showed that the median PFS rate of the BEV group was significantly higher than that of the Non-BEV group ($P < 0.00001$). When comparing PFS between two groups, we found that the PFS in the BEV group was higher than that in the Non-BEV group at 6 months (OR 3.31, 95%CI 2.74 to 4.00, $p < 0.00001$), 12 months (OR 2.05, 95%CI 1.70 to 2.49, $p < 0.00001$) and 18 months (OR 1.31, 95%CI 1.02 to 1.69, $p = 0.03$). But at 24 months (OR 0.83, 95%CI 0.50 to 1.37, $p = 0.47$), there was no significant difference between the two groups. At 30 months (OR 0.62, 95%CI 0.39 to 0.97, $p = 0.04$), the PFS of the BEV group was lower than that of the Non-BEV group. Moreover, The results showed that BEV had no significant effect on improving OS, but the adverse reaction in BEV group was significantly higher than that in non-BEV group.

Conclusion: The evidence suggests that BEV can significantly prolong the PFS of patients with glioma within 18 months and shorten the PFS of patients after 30 months. This limitation may be related to the subgroup of patients, the change of recurrence mode, the optimal dose of drug, the increase of hypoxia, the enhancement of invasiveness and so on. Therefore, it is necessary to carry out more samples and higher quality large-scale research in the future.

Strengths and Limitations of this study

1. We used the Cochrane criteria to assess the risk of bias.
2. The heterogeneity was explored by sensitivity, sub-group.

3. the quality of included studies was largely moderate to high.
4. The preoperative symptoms and the scope and degree of surgical resection are not taken into account.

INTRODUCTION

Brain glioma is the most common primary intracranial tumor, accounting for about 27% of central nervous system tumors and 80% of intracranial malignant tumors¹. The median survival time reported with brain glioma is 14-16 months². The Surgical intervention combined with radiotherapy and chemotherapy are often followed for treatment of such cases, but because of its high invasive nature, it often relapses in a short time with poor prognosis. The emergence of temozolomide has considerably delayed the development of glioma to some extent, but the survival rate and quality of life of patients are still very low. Therefore, looking for better drugs to prevent and delaying the postoperative recurrence of glioma have become the focus of current research. In recent years, more and more studies have shown that malignant glioma is the tumor with the highest degree of vascularization³. The nature of proliferation is characterized by obvious proliferative vascular lumen and with abnormal proliferation of neovascularization which participates in the construction of tumor microenvironment⁴. It is closely related to the growth, invasion, and metastasis of the tumor, and positively correlated with the extent of malignancy and prognosis of the tumor. Recently, the unique biological characteristics of gliomas indicated that angiogenic factors may play an important role in its treatment and have become the focus of research.

Humanized anti-vascular endothelial growth factor monoclonal antibody-bevacizumab⁵, as a representative drug of anti-angiogenic therapy, was approved for recurrent glioblastoma by FDA in 2009⁶ and was listed in China in 2010 by CFDA. According to the radiological response rate, bevacizumab has been approved for recurrent glioblastoma in the United States and many other countries^{7,8}. Although bevacizumab (BEV) has become an important part of HGG therapy, the safety and long-term efficacy of BEV are not clear. Therefore, we conducted a clinical meta-analysis to evaluate the safety and adverse reactions of BEV in patients with HGG, in order to provide a reference for clinical application.

METHODS

This study was mainly based on the literature research, hence there is no need for ethical identification.

Patient and Public Involvement

1
2
3
4 No patients or members of the public were involved in the design or conduct of
5 this study
6
7

8 **Search strategy**

9
10 We collected all the clinical experimental studies of anti-angiogenic therapy in
11 the treatment of gliomas, retrieved through a database search including PubMed,
12 Embase, The Cochrane Library, WanFang, Chinese periodical full-text database (CNKI),
13 and Chinese biomedical literature service system (CBM), the time span is from the
14 establishment of the database to April 2020. The search strategy followed included
15 a combination of subject words and free words, and the retrieval strategy was
16 determined after several pre-searches. The main search words included: "glioma",
17 "angiogenesis inhibitors", "vascular endothelial growth factors", "VEGF", and
18 "clinical study". Additionally, we also manually searched the reference list of all
19 articles on this topic to check and enhance the retrieval of other related publications.
20 All search results are evaluated according to the (PRISMA) statement of "preferred
21 reporting items for systematic review and meta-analysis".
22
23
24
25
26
27
28
29

30 **Selection criteria**

31 Studies were included if they fulfilled the following criteria: (1) Study subjects:
32 the participants were adults aged 18 years and above, whose histology was
33 confirmed to be malignant glioma. They may have undergone some form of surgery
34 to achieve histological diagnosis (biopsy or resection); (2) Study type: The clinical
35 control study; (3) Intervention: bevacizumab group must include bevacizumab,
36 which can be used alone or in combination with multiple drugs. The control group
37 (Non-BEV) refers to treatment that did not include anti-angiogenesis agents, which
38 can be placebo or supportive therapy, or active intervention (such as chemotherapy).
39 (4) Outcome indicators: included in accordance with the following arbitrary outcome
40 indicators: ① main indicators: progression-free survival rate, defined as the time from
41 randomization to death or disease progression of any cause, and overall survival
42 rate, defined as the time from randomization to death. ② key indicators: adverse
43 events classified according to the World Health Organization (WHO) or the General
44 terminology Standard of the National Cancer Institute (NCI-CTCAE (CTCAE2017)),
45 including the percentage of treatment-related deaths.
46
47
48
49
50
51
52
53

54 Studies were excluded if they fulfilled the following conditions: Non-clinical
55 control studies, incomplete abstract information, conference papers, reviews, and
56 case reports. In addition, the literature of repeated publication and incomplete data
57 that cannot extract valid data were excluded.
58
59
60

Data extraction

Literature screening, data extraction, and cross-checking were carried out by two independent researchers according to the initial inclusion and exclusion criteria, if there were any differences, they were discussed or judged with the assistance of a third person. For missing data, we contacted the author if possible. During the literature screening, the title and the abstract were read initially, after excluding obviously irrelevant literature, the full text was read to determine whether to include it or not. Upon matching the inclusion criteria of requirements, the following contents were extracted: (1) the basic information, including title, author, published country, publication date, research type; (2) study subjects, including the number of cases in each group, average age; (3) interventional factors, including the specific details of exposure factors, follow-up time, etc.; and (4) the outcome indicators.

Quality assessment

Using the Cochrane collaboration tool, the risk of bias in individual studies was assessed from seven aspects (sequence generation, allocation hiding, uninformed participants and people, incomplete outcome data, selective reports, and other biases and risks)⁹. Finally, each project was evaluated at three levels: low risk, unclear, and high risk. The two authors conducted independent quality assessments and any differences among them were resolved through discussions with a third research expert.

Statistical analysis

Analysis of outcome index

PFS, OS, and adverse reactions were analyzed by Meta with RevMan5.1 software. The dichotomy data is expressed as the combined risk ratio (RR) or risk ratio (hazard ratio; HR), The measurement data is expressed as the mean difference (WMD). The interval estimation was expressed by 95%CI, and the test level of the effect quantity was $\alpha = 0.05$. The test for heterogeneity used I^2 statistics. If there is no significant heterogeneity among studies ($I^2 \leq 50\%$), we used the fixed effects model for data consolidation. While there is significant heterogeneity ($I^2 > 50\%$) between the results of the study, the random effects model for data analysis would be used.

Sensitivity analysis

Simultaneously, stata15.1 was used for sensitivity analysis, adopt the method of examining the impact of individual studies and eliminate them one by one, if the

value obtained is within the confidence interval on both sides, the result is stable. otherwise, they were regarded as unstable. If the results are unstable, it is proved that the elimination research has a great impact on the overall research results. We will conduct a professional analysis of the elimination research to find out the reasons for its impact on the results and study it. Studies included in literature > 10 were used to detect publication bias by funnel chart.

RESULT

Literature screening

A total of 1108 related literature were obtained in the initial examination. After screening the literature one by one, a total of 1123 patients were included in 11 clinical studies¹⁰⁻²⁰. The flow chart and the results of literature retrieval are shown in figure 1.

The basic characteristics of the inclusion study

For the inclusion study, the basic information for inclusion is completed using pre-developed forms (Tables 1, 2).

Table 1: basic information for inclusion in the study

Study	State	Res earc h type	Cases (experime ntal/ control)	Ages(exper imental / control)	Follow-up time	Outcome
Olivier L. Chinot, M.D ^{2014[10]}	France	RCT	458/463	20-84/18- 79	The last patient was hospitalize d for 17 months.	1and2year survival rates 、 safety and quality of life、 PFS 、 OS
Qianru Zhao ^{2016[11]}	China	RCT	25/24	24-71/27-	The median follow-up time was 7.9 months	disease control rate 、 median survival time、 OS 、 PFS

Ulrich Herrlinge r ²⁰¹⁶ [12]	German y	RCT	116/54	25-78/26- 78	Long-term follow-up until death	PFS-6, PFS, OS
Mark R.Gilbert 2016[13]	German y	RCT	320/317	>18	6 cycles	OS, PFS
Clara Chen 2014[14]	Americ a	Non- RCT	57/79/23	30-77/24-82/19-78	>1year	OS, PFS, Adverse reactione
Hualong Li ²⁰²⁰ [15]	China	RCT	31/31	18-70/19- 69	4 months	PFS6, DCR, Adverse reaction
Zhixian Zhang 2018 ^[16]	China	RCT	20/20	24-74	5.2- 18months	PFS6, OS12
Jiaqi Wang ²⁰¹³ [17]	China	RCT	27/27	53.6 ± 9.7 /54.7 ± 8.8	6months- 2years	RR, DCR, Adverse reaction
Albert Lai ²⁰¹⁰ [18]	Americ a	RCT	70/110	31.3- 75.8/20.5- 90	>42months	OS, PFS, Adverse reaction
B.Chauff ert ²⁰¹⁴ [19]	Britain	RCT	60/60	43-69/43- 71	6 months	OS, PFS, Adverse reaction
Carmen Balana ²⁰¹ 6[20]	Spain	RCT	48/45	36-75/43- 75		OS, PFS, Adverse reaction

Table 2: basic characteristics of the inclusion study

Study	Male	Female	Open biopsy	Partial resectio	Complete resection	experimental/control
Olivier L. Chinot, M.D. ²⁰¹⁴	282 (61.6) /298 (64.4)	176 (38.4) /165 (35.6)	60 (13.1) /44 (9.5)	210 (45.9) /223 (48.2)	188 (41.0) /196 (42.3)	Bevacizumab+ RT - TMZ/ Placebo+RT - TMZ
Qianru Zhao ²⁰¹⁶	14/12	11/12	/	15/16	10/8	BEV+TMZ/TMZ
Ulrich Herrlinge r ²⁰¹⁶	80 (69.0) /34 (63.0)	36 (31.0) /20 (37.0)	0/2 (3.7)	58 (50.0) /27 (50.0)	58 (50.0) /25 (46.3)	BEV+IRI/TMZ
Mark R.Gilbert ²⁰¹⁶	/	/	/	/	/	Bevacizumab/ Placebo
Clara Chen ²⁰¹⁴	30 (53) /45 (57) /15 (65)	57/79/23 27 (47) /34 (43) /8 (35)	34 (60) /4 4 (56) /14 (61)	20 (35) /33 (42) /9 (39)	3 (5) /2 (2) / 0 (0)	Bevacizumab monotherapy /Bevacizumab combination /Nonbevacizumab
Hualong Li ²⁰²⁰	19/18	12/13	/	/	/	TMZ+BEV/TMZ

Zhixian Zhang ²⁰¹⁸	22	18	/	18	22	BEV+TMZ/ Gamma knife +TMZ/
Jiaqi Wang ²⁰¹³	16/14	11/13	/	/	/	TMZ+BEV/TMZ
Albert Lai ²⁰¹⁰	31/40	39/70	2/23	40/40	28/47	RT+TMZ+BV/UC LA/KPLA Control RT/TMZ
B.Chauffert ²⁰¹⁴	26/23	34/37	/	/	/	BEV+IRI/TMZ Z+RT
Carmen Balana	31/25	17/20	42/35	/	/	TMZ+BEV/TMZ

Risk of bias assessment

The results of the bias risk assessment included in the study are shown in figure 2.

Meta-analysis results

Progression-free survival

Seven studies^{10,12-14,18-20} reported median progression-free survival (BEV group, n=1160) and Non-BEV group (n=1027). There was no significant difference in the heterogeneity test ($I^2=34% < 50%$), so the fixed effect model was used for data analysis. Results suggested that the median progression-free survival of gliomas treated with BEV was significantly longer than that of malignant gliomas treated with Non-BEV (HR 0.71, 95%CI, 0.65 to 0.78, $P < 0.00001$), As shown in figure 3.

Ten studies¹⁰⁻¹⁹ compared PFS ratios at different follow-up between the Bev group and the Non-BEV group. There was a significant difference in the total heterogeneity test ($I^2=71% > 50%$), so the random effect model was used. Through the results found it was found that the PFS in the BEV group was higher than that in the Non-BEV group at 6 months (OR 3.31, 95%CI 2.74 to 4.00, $p < 0.00001$), 12

1
2
3
4 months (OR 2.05, 95%CI 1.70 to 2.49, $p < 0.00001$) and 18 months (OR 1.31, 95%CI
5 1.02 to 1.69, $p = 0.03$). But at 24 months (OR 0.83, 95%CI 0.50 to 1.37, $p = 0.47$), $P >$
6 0.05, so there was no significant statistical difference between the two groups. At 30
7 months (OR 0.62, 95%CI 0.39 to 0.97, $p = 0.04$), $0.61 < 1$, the diamond pattern falls
8 on the group that supports Non-BEV group, so the PFS of the BEV group was lower
9 than that of the Non-BEV group, as shown in figure 4.

Overall survival time

14 Seven studies^{10,12-14,18-20} reported the median overall survival time, and
15 there was a significant difference in the total heterogeneity test ($I^2 = 71\% > 50\%$), so
16 the random effect model was used. Results suggesting that there was no significant
17 difference in median overall survival time between the BEV group and Non-BEV
18 group (HR 0.90, 95%CI, 0.73 to 1.10, $P = 0.30$), as shown in figure 5.

22 Six studies^{10,12-14,18-19} compared OS ratios at different follow-up between the
23 Bev group and the Non-BEV group. there was no significant difference in the
24 heterogeneity test ($I^2 = 38\% < 50\%$), so the fixed effect model was used for data
25 analysis. Through the results found it was found that the OS in the BEV group was
26 higher than that in the Non-BEV group at 6 months (OR 1.41; 95%CI, 1.07-1.84;
27 $P = 0.01$), 12 months (OR 1.31; 95%CI, 1.09-1.58; $P = 0.005$). But at 18 months (OR
28 0.95; 95%CI, 0.79-1.14; $P = 0.58$), 24 months (OR 1.10; 95%CI, 0.89-1.35;
29 $P = 0.39$), and 30 months (OR 0.90; 95%CI, 0.69-1.18; $P = 0.44$), $P > 0.05$, so
30 there was no significant statistical difference between the two groups, as shown in
31 figure 6.

Adverse reaction

37 As shown in figure 7, there were six studies^{10-11,13-15} that compared adverse
38 reactions between the BEV group and the Non-BEV group. There was a significant
39 difference in the total heterogeneity test ($I^2 = 54\% > 50\%$), and the random effect
40 model was used. The results showed the combined OR values of hypertension,
41 hemorrhage, hematencephalon, albuminuria, and thromboembolism as follows:
42 hypertension (OR 5.14, 95%CI 3.79 to 6.96, $P < 0.00001$), hemorrhage (OR 2.62,
43 95%CI 1.96 to 3.49, $P < 0.00001$), hematencephalon (OR 2.26, 95%CI 1.08 to 4.72,
44 $P = 0.03$), albuminuria (OR 4.04, 95%CI 2.56 to 6.37, $P < 0.00001$) and
45 thromboembolism (OR 1.57, 95%CI 0.88 to 2.77, $P = 0.13$). Through the results found
46 it was found that the adverse reactions in the BEV group was higher than that in the
47 Non-BEV group.

Sensitivity analysis

51 The sensitivity test was used to evaluate the stability of OS, PFS, and adverse
52 reactions in the included literature, which showed that all values remained in the
53
54
55
56
57
58
59
60

confidence interval on both sides after one by one elimination. Hence, it can be concluded that all the included literature is stable, as shown in figures 8,9.

Publication bias

As shown in figures 10, the funnel chart was mainly concentrated at the top. Moreover, the symmetry was also proper, so it was concluded that the possibility of publication bias was small.

DISCUSSION

According to histopathological and clinical features, gliomas are divided into astrocytoma, oligodendroglioma, oligodendroglioma and ependymoma, which are the most common malignant tumors derived from neuroepithelium. Although the technical level of surgery, radiotherapy and chemotherapy²¹ in the treatment of glioma has been greatly improved, but the recurrence rate and mortality rate are still high, so there is an urgent need for a new treatment. Glioma affects the body through a variety of pathophysiological processes, in which angiogenesis plays an important role in the occurrence and development of glioma, so blocking angiogenesis has become a new direction of treatment. Bevacizumab is an anti-(VEGF) antibody against vascular endothelial growth factor²², which acts mainly by competing against VEGF, and binding to VEGFR on the target cell membrane. Pope²³ and other studies have shown that the high surface of VEGF affects blood vessel density and tumor grade. Some studies have shown that Ang2/Tie2^{24,25} and STAT3²⁶ are two important signal pathways in anti-angiogenic therapy, which play a good role in inhibiting peritumoral edema and the increase of neurological symptoms. In order to better understand the advantages and disadvantages of BEV on glioma, this study has a better understanding of the efficacy and safety of BEV through systematic review.

The results of our study showed that the PFS of BEV group was higher than that of Non-BEV group during the follow-up period of < 18 months, but when the follow-up time was 30 months, the PFS of BEV group was lower than that of Non-BEV; meanwhile, It was found that the OS in the BEV group was higher than that in the Non-BEV group at 6 months,12 months, but after 12 months, there was no statistically significant difference between the BEV group and the non-BEV group. The study of Li YD²⁷ showed that the progression-free survival time at 24 months and 36 months in the bevacizumab group was lower than that in the non-bevacizumab group; The results of LiaoKL²⁸ showed that a higher incidence of PFS could be obtained by adding BEV to newly diagnosed GB, and this combined treatment did not improve OS. The AVAglia²⁹ trial showed that patients treated with bevacizumab had significant advantages in PFS (6.2 months vs. 10.6 months) and

1
2
3
4 maintenance of life quality, but showed no advantages in OS (16.8 months vs. 16.7
5 months).2.2% of patients treated with bevacizumab confirmed false progression,
6 compared with 9.3% of patients treated with non-bevacizumab.Vredenburgh³⁰
7 found in a single-group clinical phase 2 experimental study that the median PFS of
8 bevacizumab combined with temozolomide and radiotherapy reached nearly twice
9 the standard of 3-14 months, however the overall survival was not significant
10 Improvement.Chinot³¹ and Gilbert³² conducted phase 3 clinical trials with a placebo
11 control group, the results showed that PFS increased by 40%-71% compared with
12 the control group. Special related research on OS, Brandes³³ and Wick³⁴ also found
13 that BEV failed to improve OS of patients with glioma in a randomized study
14 analyzing bevacizumab. From the above research, BEV can improve the PFS of
15 glioma patients within 18 months, but the PFS of patients may be reduced after 30
16 months. It has no obvious significance to improve OS.

17
18
19
20
21
22
23
24 This study showed that after the application of BEV, there were five common
25 adverse reactions: hypertension, hemorrhage, hematencephalon, albuminuria and
26 thromboembolism. A phase II trial of Japanese³⁵ showed that the most common side
27 effects were albuminuria, hypertension, hemorrhage, fever and epilepsy. Studies³⁶
28 showed that the incidence of adverse reactions above grade 3 was 27.1% to 46.4%,
29 the most common events were thromboembolism, hypertension, epilepsy, fatigue
30 and intestinal perforation. Zhang Li³⁷ searched 20 articles about adverse reactions
31 caused by BEV, and found that the main adverse reactions were cardiovascular and
32 hematological diseases. Norden³⁸ evaluated 64 glioma patients who received BEV
33 anticoagulant therapy and 64 glioma patients who did not receive anticoagulant
34 therapy, The results showed that the incidence of intracranial hemorrhage and other
35 bleeding in patients treated with anticoagulants was significantly higher than that in
36 patients with BEV alone, but the incidence of severe intracranial hemorrhage was
37 within an acceptable range. Therefore, when using bevacizumab clinically, it is
38 necessary to closely observe drug adverse reactions, monitor blood pressure,
39 coagulation function and other indicators, and deal with symptoms in time.

40
41
42
43
44
45
46
47
48 From the above research results, it can be concluded that long-term use of BEV
49 does not increase the patient's PFS, BEV can improve the PFS of glioma patients
50 within 18 months, but the PFS of patients may be reduced after 30 months. Nagham
51 Kaka found³⁹ that BEV could have a role in the treatment of particular subgroups of
52 patients with newly diagnosed GBM. Several studies^{40,41} have found that the median
53 PFS of patients with methylation is longer than that of MGMT unmethylated tumors
54 treated with RT and TMZ combined with BEV. Sandmann and colleagues⁴² found
55 that BEV combined with standard TMZ and RT can improve the survival rate of
56
57
58
59
60

1
2
3
4 neurotumors, while poorly differentiated mesenchymal tumors may make tumors
5 resistant to BEV over time. Adilijiang and Colleagues⁴³ found that treatment with
6 BEV and TMZ results in the upregulation of certain microenvironment related genes
7 in IDH1 mutant tumors in vitro, specifically those involving immune response and
8 extracellular matrix organization. Therefore, The question of whether the limitation
9 of BEV in the treatment of gliomas is due to fixed subsets deserves constant
10 attention.
11
12
13

14 Studies have shown^{44,45} that antiangiogenic therapy can lead to a transition of
15 glioma to a more aggressive phenotype. In retrospective analysis^{46,47} a trend toward
16 enhanced infiltrative disease was seen in bevacizumab-treated glioma patients
17 suggesting that enhanced tumor inhibition may be a consequence of VEGF
18 signaling blockade. Shiao-Pei Weathers⁴⁸ shows that determining the best biological
19 dose and the subgroup of patients most likely to obtain long-lasting benefits can
20 improve the durability of bevacizumab. Victor A Levin⁴⁹ found treatment for recurrent
21 GBM with BEV appears to improve survival at a dose lower than that in the FDA
22 drug insert. Study⁵⁰ suggest that the higher dosage of BEV utilized may have
23 impacted survival benefits. Animal models⁵¹ also suggest that higher dose of anti-
24 VEGF treatment, resulting in more hypoxia, may increase tumor aggressiveness.
25 Ryota Tamura⁵² found that high doses and long-term use of anti-VEGF/VEGFR may
26 lead to hypoxia. Shiao-Pei Weathers⁴⁸ proposed in tumors where excessive vascular
27 pruning takes place, hypoxia exacerbated by antiangiogenic therapy is likely
28 responsible for initiating a cascade of events. As mentioned above, there are many
29 possible reasons for the limited efficacy of antiangiogenic therapy. But The lack of
30 a long-lasting response to current antiangiogenic treatment underscores the need
31 for a better understanding of how to use antiangiogenic therapy to optimize radiation
32 and chemotherapy treatments.
33
34
35
36
37
38
39
40
41
42
43

44 **CONCLUSIONS**

45 The evidence suggests that BEV can significantly prolong the PFS of patients
46 with glioma within 18 months and shorten the PFS of patients after 30 months. This
47 limitation may be related to the subgroup of patients, the change of recurrence mode,
48 the optimal dose of drug, the increase of hypoxia, the enhancement of invasiveness
49 and so on. BEV treatment has no obvious meaning in improving OS, and it has some
50 side effects, which are acceptable, but we still need to pay close attention to it and
51 take active measures to reduce the side effects. Therefore, it is necessary to carry
52 out more samples and higher quality large-scale research in the future.
53
54
55
56

57 **Declaration:**

58
59
60

Contributors WH and GJX contributed to conception and design. WH、WTZ and WK contributed to data acquisition or analysis and interpretation of data. WH、GJX、WTZ、WZJ and STZ were involved in drafting the manuscript or revising it critically for important intellectual content. All authors have given final approval of the version to be published.

Funding This study was funded by The First Affiliated Hospital of Xi'an Jiaotong University. The funder had no role in the design of the study, the collection, analysis or interpretation of data, the writing of the report or the decision to submit the paper for publication. Award/Grant number is not applicable.

Ethics Approval This study belongs to data research and is not applicable to ethical review.

Competing interests None declared.

Competing interests of Reviewer: None

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing All data relevant to the study are included in the article or uploaded as supplementary information.

All the illustrations are as follows:

Figure 1: document screening process and results

PubMed (n=259), The Cochrane Library (n=153), EMbase (n=155), CNKI (n=118), CBM (n=358), WanFang (n=65).

Figure 2: bias risk assessment form

Figur 3:HR of median PFS in BEV group and Non-BEV group in the treatment of glioma

Figur 4:OR of PFS at each follow-up time in BEV group and Non-BEV group in the treatment of glioma

Figure 5:HR of median OS in BEV group and Non-BEV group in the treatment of glioma

Figure 6: OR of OS at each follow-up time in the treatment of glioma in the BEV group and Non-BEV group

Figure 7: OR of adverse reactions in the treatment of glioma in the BEV group and Non-BEV group

Figure 8:A: the sensitivity analysis of PFS6 ;B: the sensitivity analysis of PFS12; C:the sensitivity analysis of PFS18;D:the sensitivity analysis of PFS24;E:the sensitivity analysis of PFS30

1
2
3
4 Figure 9:A: the sensitivity analysis of OS6 ;B: the sensitivity analysis of OS12; C:the
5 sensitivity analysis of OS18;D:the sensitivity analysis of OS24;E:the sensitivity
6 analysis of OS30

7
8 Figure 10:A: funnel chart of PFS at each follow-up time;B: funnel chart of OS at
9 each follow-up time
10
11
12

13 REFERENCES

- 14 1 Brem S,Tsanaclis AM,Gately S,et al.Immunolocalization of basic fibroblast growth
15 factor to the microvasculature of human brain tumors. *Cancer* 1992; 70: 2673-80.
16 2 Xia S,Lal B,Tung B,et al.Tumor microenvironment tenascin-C promotes
17 glioblastoma invasion and negatively regulates tumor proliferation.*Neuro Oncol*
18 2015;18:507 -517.
19 3 Stupp R,Pavlidis N,Jelic S,et al.ESMO Minimum Clinical Recommendations for
20 diagnosis, treatment and follow-up of malignant glioma. *Ann Oncol* 2005; 16 Suppl
21 1:i64-5.
22 4 Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration' s tool
23 for assessing risk of bias in randomised trials. *BMJ* 2011; 343:d5928.
24 5 Sweet JA, Feinberg ML, Sherman JH. The role of avastin in the management
25 of recurrent glioblastoma. *Neurosurg Clin N Am* 2012;23:331-341.
26 6 Cohen MH, Shen YL, Keegan P, et al. FDA drug approval summary:
27 bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.*Oncologist*
28 2009;14:1131-1138.
29 7 Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed
30 by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J*
31 *Clin Oncol* 2009; 27:740 - 5.
32 8 Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al.
33 Bevacizumab alone and in combination with irinotecan in recur-rent glioblastoma. *J*
34 *Clin Oncol* 2009; 27:4733 - 40.
35 9 Gs HJP. Cochrane handbook for systematic reviews of interventions version 5.1.0
36 (updated March 2011).*Naunyn-Schmiedebergs Archiv für Experimentelle Pathologie*
37 *und Pharmakologie* 2014;5:S38.
38 10 Olivier L. Chinot, M.D., Wolfgang Wick, M.D., Warren Mason, et al. Bevacizumab
39 plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma. *The New*
40 *England Journal of Medicine* 2014; 370:709-722.
41 11 Zhao Qianru. Efficacy and safety of bevacizumab combined with temozolomide
42 in the treatment of recurrent malignant gliomas. Zhengzhou University, 2016.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 12 Ulrich Herrlinger, Niklas Schäfer, Joachim P, et al. Bevacizumab Plus Irinotecan
5 Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA
6 Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.
7 Journal of clinical oncology 2015; 63:4691.
8

9
10 13 Mark R. Gilbert, James J. Dignam, Terri S. Armstrong, et al. A Randomized Trial
11 of Bevacizumab for Newly Diagnosed Glioblastoma. The New England Journal of
12 Medicine 2014;370:699-708.
13

14 14 Clara Chen,rliene Ravelo,Elaine Yu,et al.Clinical outcomes with bevacizumab-
15 containing and non-bevacizumab - containing regimens in patients with recurrent
16 glioblastoma from US community practices.CLINICAL STUDY 2015;DOI
17 10.1007/s11060-015-1752-y.
18

19 15 Li Hualong, Qiang Ming, Huang Xiaoqin, et al. Efficacy of bevacizumab combined
20 with temozolomide in the treatment of malignant recurrent gliomas. Anhui
21 Medicine,2020;41:66-68.
22

23 16 Zhang Zhixian, Gu Hou, Lin Jian, et al.Clinical efficacy of gamma knife combined
24 with bevacizumab in the treatment of postoperative malignant gliomas. Journal of
25 Kunming Medical University 2018;39:33-37.
26

27 17 Wang Jiaqi, Liang Yong, Ouyang Zheng, et al. Clinical analysis of bevacizumab
28 combined with temozolomide in the treatment of glioblastoma. Oncology Pharmacy
29 2013;3:274-277.
30

31 18 Albert Lai,Anh Tran,Phioanh L,et al.Phase II Study of Bevacizumab Plus
32 Temozolomide During and After Radiation Therapy for Patients With Newly
33 Diagnosed Glioblastoma Multiforme.JOURNAL OF CLINICAL ONCOLOGY
34 2010;30:2709.
35

36 19 Chauffert B,Feuvret L,Bonnetain F, et al. Randomized phase II trial of irinotecan
37 and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based
38 chemoradiation compared with temozolomide-chemoradiation for unresectable
39 glioblastoma: final results of the TEMAVIR study from ANOCEF. Annals of Oncology
40 Official Journal of the European Society for Medical Oncology 2014;25:1442.
41

42 20 Carmen Balana,Ramon De Las Penas,Juan Manuel Sepu'lveda, et
43 al.Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant
44 treatment in unresected glioblastoma:the GENOM 009 randomized phase II trial. J
45 Neurooncol 2016;DOI 10.1007/s11060-016-2065-5
46

47 21 Lu Yuntao, Qi Songtao, Ouyanghui, et al. Surgical and therapeutic strategies for
48 recurrent malignant gliomas in refractory sites.Chinese Journal of Modern
49 Neurological Diseases 2012;12 (6): 682-690.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 22 Cheng Haixia,Wang Yin. Hair cell astrocytoma with vascular central arrangement:
5 case report and literature review.Chinese Journal of Modern
6 Neurology.2013;13:342-348.
7
8 23 Pope WB,Xia Q,Paton VE,et al.Patterns of progression in patients with recurrent
9 glioblastoma treated with bevacizumab.Neurology 2011;76:432-437.
10
11 24 Park JS,Kim IK,Han S,et al.Normalization of tumor vessels by Tie2 activation and
12 Ang2 inhibition enhances drug delivery and produces a favorable tumor
13 microenvironment. Cancer Cell 2016;30:953—967.
14
15 25 Labussiare M,Cheneau C,Praht C,et al.Angiopietin-2 may be involved in the
16 resistance to bevacizumab in recurrent glioblastoma. Cancer Invest 2016; 34:39—
17 44.
18
19 26 Groot J,Liang J,Kong LY,et al . Modulating antiangiogenic resistance by
20 inhibiting the signal transducer and activator of transcription 3 pathway in
21 glioblastoma.Oncotarget 2012;3(9):1036-1048.
22
23 27 Li Y,Hou M,Lu G,et al.The Prognosis of Anti-Angiogenesis Treatments Combined
24 with Standard Therapy for Newly Diagnosed Glioblastoma: A Meta-Analysis of
25 Randomized Controlled Trials. Plos One 2016,11:e0168264.
26
27 28 Liao KL,Huang S,Wu YP.The prognosis for patients with newly diagnosed
28 glioblastoma receiving bevacizumab combination therapy: a meta-analysis.
29 OncoTargets and therapy 2018;11:3513-3520.
30
31 29 Chinot O, Cloughesy T, Henriksson R, et al. Efficacy and safety of bevacizumab
32 (Bv) plus standard combination temozolomide (T) and radiotherapy (RT) in newly
33 diagnosed glioblastoma: final results from a AVA glo. Eur J Cancer 2013; 49(suppl
34 2):S774-5.
35
36 30 Vredenburgh JJ, Desjardins A, Kirkpatrick JP, et al. Addition of bevacizumab to
37 standard radiation therapy and daily temozolomide is associated with minimal
38 toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys
39 2012;82:58-66.
40
41 31 Chinot OL,Wick W,Mason W,et al. Bevacizumab plus radiotherapy-temozolomide
42 for newly diagnosed glioblastoma. N Engl J Med 2014;370:709 - 22.
43
44 32 Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab
45 for newly diagnosed glioblastoma. N Engl J Med 2014;370:699 - 708.
46
47 33 Brandes, A.A.,Finocchiaro, G.,Zagonel, V.,et al.Final results from the
48 randomized phase II trial average (ML25739) with bevacizumab or fotemustine in
49 recurrent GBM. Neuro-Oncol 2014;16:v8 - v22.
50
51 34 Wick, W.,Brandes, A.A.,Gorlia, T.,et al.Phase III trial exploring the combination
52 of bevacizumab and lomustine in patients with first recurrence of a glioblastoma:
53 the EORTC 26101 trial.Neuro-Oncol 2015;17:v1.
54
55
56
57
58
59
60

1
2
3
4 35 Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination
5 with irinotecan in recurrent glioblastoma. *J Clin Oncol*.2009;27:4733 – 40.

6
7 36 Nagane M,Nishikawa R,Narita Y,et al.Phase II study of single-agent
8 bevacizumab in Japanese patients with recurrent malignant glioma.*Jpn J Clin Oncol*
9 2012;42:887 – 95.

10
11 37 Zhang Li. Statistical analysis of adverse reactions caused by bevacizumab.
12 *Clinical Medical Engineering* 2012;19:129-130.

13
14 38 Norden AD,Bartolomeo J,Tanaka S,et al.Safety of concurrent bevacizumab
15 therapy and anticoagulation in glioma patients. *J Neurooncol* 2011;106:121-125.

16
17 39 Nagham Kaka,Karim Hafazalla,Haider Samawi,et al.Progression-Free but No
18 Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the
19 Treatment of Newly Diagnosed Glioblastoma:A Systematic Review and Meta-
20 Analysis.*Cancers* 2019;11:1723.

21
22 40 Chinot, O.L.;Wick, W.;Mason, W.;et al.Bevacizumab plus radiotherapy-
23 temozolomide for newly diagnosed glioblastoma.*New Engl. J. Med* 2014;370:709 –
24 722.

25
26 41 Gilbert, M.R.;Dignam, J.J.;Armstrong, T.S.;et al.A randomized trial of
27 bevacizumab for newly diagnosed glioblastoma. *New Engl.J.Med* 2014;370:699 –
28 708.

29
30 42 Phillips, H.S.;Kharbanda, S.;Chen, R.;et al. Molecular subclasses of high-grade
31 glioma predict prognosis, delineate a pattern of disease progression, and resemble
32 stages in neurogenesis.*Cancer Cell* 2006;9:157 – 173.

33
34 43 Adilijiang, A.;Hirano, M.;Okuno, Y.;et al.Next generation sequencing-based
35 transcriptome predicts bevacizumab efficacy in combination with temozolomide in
36 glioblastoma. *Molecules* 2019;24:3046.

37
38 44 Piao Y , Liang J, Holmes L, et al. Acquired resistance to anti-VEGF therapy in
39 glioblastoma is associated with a mesenchymal transition.*Clin Cancer Res*
40 2013;19:4392 – 403.

41
42 45 Lu KV , Chang JP , Parachoniak CA, et al. VEGF inhibits tumor cell invasion and
43 mesenchymal transition through a MET/VEGFR2 complex.*Cancer Cell* 2012;22:21 –
44 35.

45
46 46 Norden A,Young G,Setayesh K,et al.Bevacizumab for recurrent malignant
47 gliomas: efficacy, toxicity, and patterns of recurrence.*Neurology* 2008;70:779 – 87.

48
49 47 Soda Y,Myskiw C,Rommel A, Verma I. Mechanisms of neovas-
50 cularization and resistance to anti-angiogenic therapies in glioblas-
51 toma multiforme. *J Mol Med (Berl)*
52 2013;91:439 – 48.

53
54 48 Shiao-Pei Weathers,John de Groot.Resistance to Antiangiogenic Therapy.*Curr*
55 *Neurol Neurosci Rep* 2014;14:443.

1
2
3
4 49 Victor A. Levin, Nancy D, et al. Mendelssohn, James Chan. Impact of bevacizumab
5 administered dose on overall survival of patients with progressive glioblastoma. J
6 Neurooncol 2015;122:145-50.

7
8 50 Lorgis V, Maura G, Coppa G, et al. Relation between bevacizumab dose intensity
9 and high-grade glioma survival: a retrospective study in two large cohorts. J
10 NeuroOncol 2012, 107:351–358.

11
12 51 Keunen O, Johansson M, Oudin A, et al. Anti-VEGF treatment reduces blood supply
13 and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA Proc Natl
14 Acad Sci U S A 2011;108:3749-54.

15
16 52 Ryota Tamura, Toshihide Tanaka, Yasuharu Akasaki, et al. The role of vascular
17 endothelial growth factor in the hypoxic and immunosuppressive tumor
18 microenvironment: perspectives for therapeutic implications. Med Oncol 2019;37:2.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: document screening process and results

34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

Figure 1: document screening process and results
PubMed (n=259), The Cochrane Library (n=153), EMBASE (n=155), CNKI (n=118), CBM (n=358), WanFang (n=65).

49
50
51
52
53
54
55
56
57
58
59
60


209x296mm (120 x 120 DPI)

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Albert Lai 2010	?	?	+	+	+	+	+
B. Chauffert 2014	+	?	+	+	+	+	+
Carmen Balana 2016	+	+	-	?	+	+	+
Clara Chen 2014	-	?	?	?	+	+	+
HuaLong Li 2013	+	?	+	+	+	+	+
JiaQi Wang 2013	+	?	+	+	+	+	+
Mark R. Gilbert 2016	+	?	+	+	+	+	+
Olivier L. Chinot 2014	+	?	+	+	+	+	-
Qianru Zhao 2016	+	?	+	+	+	+	+
Ulrich Herrlinger 2016	+	?	-	-	+	+	+
ZhiXian Zhang 2018	-	?	?	?	+	+	+


Figure 2: bias risk assessment form

209x278mm (120 x 120 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Figur 3:HR of median PFS in BEV group and Non-BEV group in the treatment of glioma
 209x278mm (120 x 120 DPI)



Figur 4:OR of PFS at each follow-up time in BEV group and Non-BEV group in the treatment of glioma

150x223mm (120 x 120 DPI)




Figure 5:HR of median OS in BEV group and Non-BEV group in the treatment of glioma

209x278mm (120 x 120 DPI)




Figure 6: OR of OS at each follow-up time in the treatment of glioma in the BEV group and Non-BEV group

148x206mm (120 x 120 DPI)




Figure 7: OR of adverse reactions in the treatment of glioma in the BEV group and Non-BEV group

209x278mm (120 x 120 DPI)




Figure 8:A: the sensitivity analysis of PFS6 ;B: the sensitivity analysis of PFS12; C:the sensitivity analysis of PFS18;D:the sensitivity analysis of PFS24;E:the sensitivity analysis of PFS30

209x296mm (288 x 288 DPI)




Figure 9:A: the sensitivity analysis of OS6 ;B: the sensitivity analysis of OS12; C:the sensitivity analysis of OS18;D:the sensitivity analysis of OS24;E:the sensitivity analysis of OS30

209x296mm (288 x 288 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 10:A: funnel chart of PFS at each follow-up time;B: funnel chart of OS at each follow-up time
209x296mm (288 x 288 DPI)



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	1
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	2
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	3
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	3
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	13-14
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	3
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	4
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	4
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	9
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	4
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	4
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	3
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	4
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	4
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	4
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	4-5
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	4-5
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	4
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	4-5



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	5
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	5
Study characteristics	17	Cite each included study and present its characteristics.	5
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	5
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	5-6
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	6
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	6
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	6
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	6
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	6
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	6
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	7-8
	23b	Discuss any limitations of the evidence included in the review.	7-8
	23c	Discuss any limitations of the review processes used.	7-8
	23d	Discuss implications of the results for practice, policy, and future research.	8
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	9
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	9
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	9
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	9
Competing interests	26	Declare any competing interests of review authors.	9
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	9